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1. Foreword 
 
To say that obesity and diabetes have reached epidemic proportions has 
become something of a cliché. This should not lead us to simply accept it as 
a byproduct of our changing lifestyle, or to overlook the socioeconomic 
importance of these conditions. 
 
Our attempts at therapeutic intervention have been hindered by a lack of 
knowledge about the precise pathophysiological mechanisms via which 
obesity triggers secondary disorders such as diabetes and cardiovascular 
problems. Our approach to understanding the mechanisms have been 
largely focused on single molecules whose levels or activity are altered in 
obesity, and which are known independently to contribute to these 
secondary disorders. Although we have accumulated genetic and 
biochemical evidence for the potential role of these factors in these disorders, 
it must be noted that no single candidate or mechanism has yet given a 
satisfactory explanation for all the obesity-related disorders. This has led 
researchers to conclude that the underlying pathology is polygenic or multi-
factorial. However, based on our experiments and the recent findings of a 
few other laboratories, we propose a unifying theory where obesity leads to 
a membrane microdomain disorder that will in turn lead to the corruption of 
multiple signaling pathways that are known to be implicated in insulin 
resistance and cardiovascular disorders. We also explore the possibility of 
pharmacologically modulating a nodal, but downstream, drug target that 
might retard or prevent these disorders. Having said that, I would like to 
clearly state that this theory is still in its infancy, and remains to be tested in 
both animal models and human subjects.  
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Summary 
 
Obesity is a major risk factor for the development of secondary disorders 
such as type-2 diabetes mellitus, cardiovascular complications and certain 
types of cancers. Quenttesentially, these secondary disorders results from 
the corruption of physiological signal transduction mechanisms. We know 
relatively well as to what these signal transduction disorders are, but how 
obesity leads to these signaling defects remains obscure. In this thesis we 
show that caveolar microdomains are a key signal transduction platform, 
whose perturbation can lead to a plethora of signaling defects that are 
known to elicit secondary-disorders of obesity. Elevated levels of PAI-1 
represent a ‘nodal’ and ‘downstream’ mediator of these signaling defects. By 
using peptide antagonists of E2F-pRB interaction, we could inhibit PAI-1 
gene expression in adipocytes without causing unwanted effects such as 
cell-cycle reentry.  In effect, this study proposes a pathological mechanism 
and pharmacological intervention strategy for obesity-driven secondary 
disorders. 
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2. General introduction 
2.1 Obesity and its medical complications 
Obesity has reached epidemic proportions globally, with more than 1 billion 
adults overweight - at least 300 million of them clinically obese - and is a 
major contributor to the global burden of chronic disease and disability (1). 
Often coexisting in developing countries with under-nutrition, obesity is a 
complex condition, with serious social and psychological dimensions, 
affecting virtually all ages and socioeconomic groups. 
Increased consumption of more energy-dense food, combined with reduced 
physical activity, have led to obesity rates that have risen three-fold or more 
since 1980 in some areas of North America, the United Kingdom, Eastern 
Europe, the Middle East, the Pacific Islands, Australasia, and China (2). The 
obesity epidemic is not restricted to industrialized societies; this increase is 
often faster in developing countries than in the developed world.  
Benchmarking obesity 
The prevalence of obesity and being overweight is commonly assessed by 
using the body mass index (BMI), defined as the weight of a person in 
kilograms divided by the square of the height in meters (kg/m2). A BMI of 
over 25 kg/m2 is defined as overweight, and a BMI of over 30 kg/m2 as 
obese (3).  
 
 
Table. 2.1: WHO guidelines for classification of overweight and obesity 
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The medical problems posed by obesity 
The problem posed by obesity is not limited to that of aesthetics. Being 
overweight or obese can lead to adverse metabolic effects on blood 
pressure, cholesterol, triglycerides, and insulin resistance (4). The non-fatal, 
but debilitating, health problems associated with obesity include respiratory 
difficulties, chronic musculoskeletal problems, skin problems, and infertility. 
The more life-threatening problems fall into three main categories: 
cardiovascular disorders (CVD); conditions associated with insulin 
resistance, such as type-2 diabetes mellitus (T2DM); and certain types of 
cancers, especially hormonally related and large-bowel cancers. 
 
Fig. 2.1.  Relationship between BMI and cardiovascular mortality. BMI is 
a strong risk factor for the development of cardiovascular disorders. 
The effects of obesity on cardiovascular health are many. Risk estimates 
from population studies suggest that 75% of hypertension can be directly 
attributed to obesity (5). It is well documented that blood pressure increases 
with weight gain and decreases with weight loss. Apart from hypertension, 
the risk for other major cardiovascular disorders, including atherosclerosis, 
dyslipedimia, and coagulation problems, are strongly increased by obesity. 
As illustrated in Fig. 2.1, BMI strongly corresponds to cardiovascular 
mortality in both men and women.  
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Fig. 2.2: Relationship 
between BMI and incidence 
of diabetes. A dramatic 
increase in the incidence of 
diabetes in over-weight and 
obese people can be seen in 
this graph. 
 
Estimates (1995) and prediction (2025) for the total 
number of diabetic patients 
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Fig. 2.3: The global 
epidemic of diabetes. 
The incidence of diabetes 
is expected to increase 
globally. Y-axis represents 
patient number in millions. 
The major economic 
power houses (USA, China, and India), which are also among the most 
populous countries in the world, are supposed to be the worst affected by 
diabetes. Source: WHO-World Health Report, 1997. 
The likelihood of developing type-2 diabetes rises steeply with increasing 
levels of body fat. The close link between the two disorders has even led to 
the coining of new term ‘diabesity’ to collectively describe this condition. 
Confined to older adults for most of the 20th century, this disease now 
affects obese children even before puberty. Approximately 85% of people 
with diabetes are type-2 and, of these, 90% are obese or overweight. And 
this is increasingly becoming a developing world problem. In 1995, the 
emerging market economies had the highest number of diabetics. If current 
trends continue, India and the Middle Eastern crescent will have taken over 
by 2025. Large increases would also be observed in China, Latin America 
and the Caribbean, and the rest of Asia.  
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Fig. 2.4. Contribution of the 
overweight and obese to mortality 
from cancer in the United States. 
Relative risk of cancer is positively 
correlated to the BMI.  
 
 
Raised BMI also increases the risk of cancer of the breast, colon, prostate, 
endometrium, kidney, and gall bladder (3). Although obesity should be 
considered a disease in its own right, it is also one of the key risk factors for 
other chronic diseases, together with smoking, high blood pressure, and 
high blood cholesterol. In the analyses carried out for the WHO World Health 
Report 2002, approximately 58% of type-2 diabetes and 21% of ischemic 
heart disease and 8-42% of certain cancers globally were attributable to a 
BMI above 21 kg/m2 (2). In the later parts of this thesis, we discuss the 
possibility of how the dysfunction of a key cellular signal-transduction 
platform known as caveolae can activate signal transduction defects that are 
characteristic of obesity-driven disorders. 
2.2 Caveolae 
Structure 
Caveolae are morphologically identifiable plasma membrane invaginations 
that are distinct from the larger electron-dense clathrin-coated pits. Originally 
identified in the 1950s by electron microscopists investigating cellular 
ultrastructure, caveolae appear as smooth, uncoated pits or vesicles at the 
plasma membrane, typically observed using conventional resin-embedded 
techniques. In general, caveolae are 50- to 100-nm flask-shaped 
invaginations of the plasma membrane that can be singular or found in 
detached grape-like clusters (rosette formation), or long, tubular structures 
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thought to evolve from the fusion of individual caveolae (Fig. 2.5) While the 
overall function of the prototypical caveolae organelle has been an area of 
intense exploration, little attention has been focused on the specialized 
function, if any, of the various morphological subsets of caveolae. 
Consequently, the functional significance of these caveolae-related 
organelles remains unknown.  
Fig. 2.5. Stylized view of the 
cell, showing the 
morphological variants of 
caveolae and selected 
subcellular compartments: 
(1) fenstra, (2) a transcellular 
channel, (3) traditional 
caveolae, (4) plasmalemmal 
vesicles (fully invaginated, static caveolae), (5) a vesiculo-vacuolar organelle 
(a grape-like cluster of interconnected caveolae and vacuoles), (6) cavicles 
(mobile, internalized caveolae not associated with the plasma membrane), 
and (7) a caveosome (a slow-moving, irregularly shaped, cytoplasmic 
organelle). 
Tissue distribution 
 
Caveolae were first identified in capillary endothelial cells and epithelial cells 
from the mouse gall bladder (6). Since then, caveolae have been identified 
in a wide variety of tissues and cell types (7). While no all-encompassing 
ultrastructural study has been undertaken, a review of published literature 
reveals that caveolae are present to some degree in most differentiated cell 
types. In particular, caveolae have been well-described in adipocytes, where 
they are extremely abundant, endothelial cells, type I pneumocytes of the 
lung, and striated and smooth muscle cells. Because of their relative 
abundance in endothelial cells and type I pneumocytes, the two major 
constituents of lung alveoli, the lung stands out as one of the most abundant 
sources of identifiable caveolae, second only to adipocytes. Ultrastructural 
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analysis of adipocytes has shown that as much as 20% of the total plasma 
membrane is occupied by caveolae (8). Thus, caveolae can greatly increase 
the surface area of numerous cell types, an observation that lends credence 
to the original speculation that caveolae are involved in macromolecular 
transport and mechanotransduction events. 
 
Biochemical properties 
Unlike earlier views of the plasma membrane as a "fluid mosaic" (9), where 
integral membrane proteins were thought to float and diffuse freely through a 
sea of homogeneous lipids, a more contemporary view of the plasma 
membrane is that proteins are much more heterogeneously distributed and 
can be found clustered within specialized microdomains, termed lipid rafts. 
These lipid rafts are thought to form via the aggregation of 
glycosphingolipids and sphingomyelin in the Golgi apparatus (held together 
by transient and weak molecular interactions) and are then delivered to the 
plasma membrane as concentrated units (10) (11). These lipid rafts are also 
enriched with cholesterol and several resident proteins, including 
glycophosphatidylinositol (GPI)-linked proteins. Relative to the plasma 
membrane proper, which contains an abundance of cis-unsaturated 
phospholipids, the sphingolipids in lipid rafts contain primarily saturated fatty 
acyl chains, allowing tighter molecular packing that results in a higher 
melting temperature (Tm 41°C vs. Tm<0°C for phospholipids) (12). The high 
cholesterol and sphingolipid content of lipid rafts imparts a resistance to 
extraction in non-ionic detergents such as Triton X-100 at 4°C, and a light 
buoyant-density in sucrose gradients, properties instrumental for their 
purification and biochemical characterization. It should be mentioned that the 
exact nature and defining characteristics of lipid rafts, as well as the 
techniques involved in isolating them, are now quite well-developed (13). 
Caveolae represent a morphologically identifiable subset of lipid rafts. They 
contain the coat protein caveolin, which is essential for the invagination of 
the plasma membrane through a largely unknown process, giving them their 
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characteristic flask-like appearance. While the overall biochemical 
composition of lipid rafts and caveolae is thought to overlap, these 
microdomains are not completely equivalent. In addition to the caveolins, 
several proteins have been shown to preferentially localize to either 
caveolae or lipid rafts (14).  
Caveolins and cholesterol: integral components of caveolae 
Fig.2.6. The structure of 
caveolae. Deep-freeze 
electron microscopy 
photograph of caveolae 
(left) and their graphical 
representation (right). 
 
Caveolae are sphingolipid- 
and cholesterol-rich invaginations of the plasma membrane, and are 
decorated intracellularly with the protein caveolin.  
 
Fig. 2.7. Schematic 
depiction of the 
caveolin gene family.  
Color-coded boxes 
indicate the exon arrangement of each caveolin family member. The 
numbers within each box refer to the number of nucleotides in each exon. 
To date, three members of the caveolin (CAV) gene family have been 
identified (15). Caveolin-1 is composed of three exons that are highly 
conserved in sequence and structure across species. Several key conserved 
caveolin-1 residues are absent or altered in caveolin-2. Human caveolin-2 is 
~38% identical and 58% similar to human caveolin-1, while caveolin-3 is 
65% identical and 85% similar to caveolin-1. Moreover, a short stretch of 
eight amino acids has been identified (FEDVIAEP) that constitutes the 
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"caveolin signature sequence," a motif that is identical in all three caveolin 
proteins. 
Caveolin (Cav)-1 and Cav-3 form 350-kd homo-oligomers made up of 14–
16 caveolin monomers. These homo-oligomers serve as the basic structural 
units that drive the formation of caveolae membranes. In contrast, Cav-2 
either homodimerizes or forms high molecular mass hetero-oligomers with 
Cav-1 (16) (17) (18). Cav-1 and Cav-3 are both independently necessary 
and sufficient to drive caveolae formation in heterologous expression 
systems, while Cav-2 requires the presence of Cav-1 for proper membrane 
targeting and stabilization. In the absence of Cav-1, Cav-2 localizes to the 
Golgi complex where it is degraded by the proteasome (19) (20). Caveolins 
1 and 2 are co-expressed in many cell types, such as endothelial cells, 
fibroblasts, smooth muscle cells, and adipocytes, where they form a 
heteroligomeric complex. In contrast, the expression of caveolin-3 is muscle-
specific.  
Fig. 2.8. Caveolin knock-out 
mice lack caveolae. Mice 
lacking caveolin-1 are shown to 
lack caveolar structures in 
alveolar epithelium (upper 
panel); Knock-out of caveolin-3 
leads to a dramatic reduction in 
caveolar structures in skeletal 
muscle (lower panel). 
 
Studies performed on knock-out mice have indicated that Cav-1 expression 
is required for caveolae formation in non-muscle cells (21), while the 
expression of Cav-3 drives caveolae formation in striated muscle cell types 
(cardiac and skeletal) (22).  
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Fig. 2.9. Depletion of cholesterol leads to caveolar dysfunction. 
Electron-microscopic analysis shows that cyclodextrin treatment dose-
dependently leads to loss of caveolae (patches), even if the caveolin (black 
spots) are unaffected. 
Moreover, it has been shown that depletion of cholesterol using cholesterol-
depleting agents such as cyclodextrin and filipin leads to perturbation of 
caveolar structure (23). Taken together, both Cav-1/3 and plasma 
membrane cholesterol appear to be critical for the structural integrity of 
caveolar microdomains. 
Physiological functions of caveolae 
 
Caveolins bind to many different molecules involved in signal transduction, 
including transmembrane receptors, G-proteins, kinases, adaptor proteins, 
and enzymes. Thus, caveolae act as a major cellular signal transduction 
platform. A short list of molecules that are known to bind to caveolae is given 
in the following table. 
 
Class of molecules Name of molecule 
Bioche
mical 
localiza
tion 
Morpholo
gical 
localizatio
n 
Ganglioside √ √ 
Sphingomyelin √ — 
Ceramide √ — 
Lipid 
  
  
  Diacylglycerol (DAG) √ — 
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  Cholesterol √ √ 
Hetero-trimeric G-proteins  √ √ 
Src, Fyn, Hck, Lck √ — 
E-NOS √ √ 
CD-36 √ — 
Acylated protein 
  
  
  
  Caveolin √ √ 
Folate receptor √ √ 
Thy 1 √ √ 
Alkaline phosphatase √ √ 
Prion √ √ 
Urokinase Rec √ √ 
Multiple GPI proteins √ — 
5'-nucleotidase √ √ 
Glycosylphospha- 
  tidylinositol 
(GPI)-anchored 
protein 
  
  
  
  CD14 √ — 
Rap1A √ √ Prenylated protein 
  Ras √ — 
Platelet-derived growth factor 
(PDGF) √ √ 
Insulin growth factor (IGF) √ √ 
Insulin — √ 
Epidermal growth factor 
(EGF) √ — 
Receptor for advanced 
glycation end product 
(RAGE) √ — 
Cholecystokinin (CCK) 
receptor √ √ 
m2 acetylcholine √   
Tissue factor √ — 
β adrenergic — √ 
Membrane receptor 
  
  
  
  
  
  
  
  
  
  
Bradykinin √ — 
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Endothelin √ —  
SR-B1 √ √ 
PKC √ √ 
SHC √ — 
SOS √ — 
GRB2 √ — 
MAP kinase √ √ 
Adenylyl cyclase √ √ 
SYP √ — 
PI3 kinase √ — 
Raf1 √ — 
Calmodulin √ — 
Phosphoinositides √   
Polyphosphoinositide 
phosphatase √ — 
Signal transducer 
  
  
  
  
  
  
  
  
  
  
  
  Engrailed √ — 
Porin √ — 
IP3 receptor √ √ 
Ca2+ ATPase √ √ 
Aquaporin-1 √ — 
Membrane 
transporter 
  
  
  
  H+ ATPase √ — 
Annexin II √ — 
Ezerin √ — 
Myosin √ — 
VAMP √ — 
NSF √ — 
MAL √ — 
Structural molecules 
  
  
  
  
  
  Actin √ √ 
Atrial natriuretic — √ 
Peptide     
Miscellaneous 
  
  Flotillin √ — 
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Table 2.2: Partial list of caveolin binding proteins [adapted from Anderson et 
al. (24)] 
 
The three well-described functions of caveolae are vesicular transport, 
cholesterol homeostasis, and, more importantly, signal transduction. It is 
important to note that, while caveolin seems to be a negative regulator of the 
vast majority of signaling proteins with which it interacts, at least one protein, 
the insulin receptor, is positively regulated by an interaction with caveolin-1 
(25) (26) (27) (28). 
 
In the later parts of this thesis, we will show that caveolar-dysfunction leads 
to increased gene-expression of plasminogen activator inhibitor-1 (PAI-1), 
whose high plasma levels are implicated in obesity associated disorders. An 
introduction to PAI-1 is given below. 
 
2.3 Plasminogen Activator System 
The plasminogen activator system represents an enzymatic cascade 
involved in the control of fibrin degradation, matrix turnover, and cell invasion. 
Extracellular proteolysis mediated by the plasminogen activator system 
plays an important role in various physiological processes such as 
angiogenesis, wound healing, inflammation, and cell proliferation (29).  
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Fig. 2.10. Schematic diagram of the plasminogen activator system and 
its role in clot lysis. PAI-1 acts as the physiological inhibitor of 
plasminogen activators, uPA, and tPA. 
 
The plasminogen activation system consists of several components 
including plasminogen, plasmin, activators, inhibitors, and a receptor (see 
Appendix-1). Plasminogen, the main component of the plasminogen system, 
is an inactive proenzyme that can be converted to the proteolytically active 
enzyme plasmin. This trypsin-like protease degrades a wide range of 
substrates, including various extracellular matrix (ECM) proteins such as 
fibronectin, vitronectin, and fibrin. Plasmin also activates matrix 
metaloproteinases and collagenases that in turn degrade ECM components 
(30).   
 
There are two physiological plasminogen activators (PA): tissue-type (tPA) 
and urokinase-type (uPA) (31). These secreted serine proteases convert the 
ubiquitous zymogen plasminogen to plasmin. The primary role of tPA is the 
generation of plasmin for fibrinolysis in blood vessels. uPA, on the other 
hand, activates plasmin for degradation of components of ECM during cell 
migration and tumor invasion.  
 
The activities of both tPA and uPA are negatively regulated by the binding of 
PA inhibitors (PAI-1 and PAI-2), protein nexin-1 (PN-1), and protein C 
inactivator (PCI). These inhibitors belong to the serine protease inhibitor 
(SERPIN) superfamily. All members of this family have in their COOH-
terminal region a specific reactive-site peptide bond (Arg-X or Lys-X), which 
is cleaved by their target enzyme, resulting in the formation of an inactive 
enzyme-inhibitor complex. The PA system also includes the uPA receptor 
(uPAR), a cell-membrane anchored uPA-binding protein. This receptor plays 
a key role in the regulation of localization, activity, function, and interactions 
among PA system components. Except for its well established role in 
proteolysis, the plasminogen activator system also supports cell migration 
and invasion by plasmin-independent mechanisms as explained earlier. 
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Physiology and regulation of PAI-1 
Plasma PAI-1 reflects the output of several sources, including the adipose 
tissue, vascular endothelium, and liver. Large quantities of PAI-1 are stored 
in platelets and render platelet-rich clots resistant to thrombolysis. Recent 
data indicate that there is a continuous production of large amounts of active 
PAI-1 in platelets (32), which could be a mechanism by which platelets 
contribute to the stabilization of blood clots. Endothelial cells in culture 
synthesize PAI-1 at relatively high rates, although in the absence of 
hormonal, metabolic, or inflammatory stimuli, the vascular endothelium is not 
likely to be a major contributor to circulating PAI-1 levels (33). Several 
different fates are possible for PAI-1 after it is synthesized and secreted. The 
majority of PAI-1 probably circulates briefly in the plasma, and only a fraction 
of the secreted, active PAI-1 has the opportunity to react with plasma t-PA, 
and form inert, covalent complexes. There appears to be no endogenous 
mechanism for recycling PA-PAI-1 complexes, which are cleared through 
the low-density lipoprotein-related (LRP) receptor (34) and the VLDL 
receptor (35). Active PAI-1 in plasma can also bind to vitronectin (36), which 
actually stabilizes PAI-1 in the active conformation. The relative abundance 
of vitronectin in the subendothelial matrix provides a mechanism for 
preserving PAI-1 activity, and it is likely that vitronectin-bound PAI-1 
represents the physiologically relevant form of the inhibitor in the 
extracellular matrix (37). 
A number of cytokines have been found to stimulate endothelial PAI-1 
production. PAI-1 is classified as an acute phase reactant, and pro-
inflammatory cytokines such as interleukin-1 (38) and tumor necrosis factor 
α (TNFα) (39) can induce PAI-1 production. These same factors are thought 
to promote vascular inflammation and atherosclerosis. Growth factors and 
hormones also regulate PAI-1 production, including transforming growth 
factor β (TGFβ)], angiotensin-II, estrogen, thrombin, and insulin (31). Of 
these factors, insulin is of particular importance since it plays an important 
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role in hyperinsulinemic conditions associated with T2DM. The role of insulin 
in PAI-1 gene expression is discussed in the later sections of this thesis. 
 
Fig. 2.11. Schematic localization of the promoter region of the human 
PAI-1 gene 
The gene for PAI-1 is located on chromosome seven, spans approximately 
12 kb, and is composed of nine exons and eight introns (40). The PAI-1 
promoter has been exhaustively characterized, yielding numerous insights 
into the molecular physiology of PAI-1. Some of the most important 
regulatory elements have been identified in the PAI-1 gene (Fig. 2.7), 
including a glucocorticoid response element that also mediates aldosterone 
responsiveness, a VLDL response site adjacent to a common diallelic 
polymorphism at −675, and two Sp1 sites that appear to mediate glucose 
and glucosamine responsiveness (33). Using cross-species sequence 
homology analysis and DNase I hypersensitive site analysis, a TNF-
responsive enhancer element was located approximately 15 kb upstream of 
the transcription start site (41). This region contains a conserved NFκB 
binding site that mediates the response to TNFα and is capable of binding 
NFκB subunit p50 and p65 in vitro. 
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Pathological role of PAI-1 
 
PAI-1 and vascular diseases 
There is substantial experimental and epidemiological evidence that PAI-1 
might contribute to the development of ischaemic cardiovascular disease 
(42). There is also experimental evidence that these epidemiological links 
are more than just a casual association. Transgenic mice that overexpress a 
stable form of human PAI-1 driven by the murine preproendothelin promoter 
develop spontaneous macrovascular coronary thrombosis and 
subendocardial myocardial infarction in the absence of hyperlipidemia or 
hypertension (43). These animals have essentially no tissue plasminogen 
activator (t-PA) activity in plasma, and also exhibit significant reductions in 
plasma levels of activated protein C. Thus, the spontaneous coronary 
thrombosis seen in these transgenic mice appears to be explained by the 
simultaneous loss of PA function and reduced protein C activity, the two 
critical pathways implicated in the defense against clotting in the coronary 
circulation (44).  
Apart from its role in thrombosis, PAI-1 also plays an important role in 
vascular and tissue remodeling. Several groups have reported excess PAI-1 
in atherosclerotic plaques in humans, a finding that is exaggerated in 
patients with T2DM (45). Metabolic derangements alone are sufficient to 
increase the arterial vascular content of PAI-1 even in the absence of 
atherosclerosis, as described in internal mammary artery sections obtained 
from patients with T2DM undergoing coronary bypass grafting (46). In 
tissues where PAI-1 is overproduced, local PA is impaired, which in turn has 
profound effects on vascular housekeeping and remodeling capacity. Indeed, 
it has been shown that PAI-1 deficiency effectively prevents the 
development of arteriosclerosis and hypertension in mice treated with the 
nitric oxide synthase inhibitor L-NAME for periods of 8–16 weeks (47). It 
seems that the increased vascular PAI-1 production and accumulation plays 
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a major role in the arterial remodeling that contributes to the development of 
hypertension in obesity and the metabolic syndrome 
PAI-1 and cancer 
 
The PA system containing serine proteases and their inhibitors, as well as a 
number of metalloproteases, is involved in extracellular proteolysis and 
tissue remodeling. Changes in the expression of components of these 
systems might reflect uncontrolled tissue remodeling and therefore promote 
cell invasion, cell migration, and proliferation (48). PAI-1 may contribute to 
the degradation of the extracellular matrix during cancer invasion by 
decreasing the adhesive strength of cells on their substratum, and detaching 
cells from extracellular matrices by inactivating integrins (49). A binding site 
for p53 in the region of the PAI-1 promoter leading to PAI-1 transcription has 
been identified (50). Strong expression of PAI-1 in tumor cells like ductal 
carcinoma in situ cells (51) or tumor tissue of squamous cell cancer (52) has 
been found while angiogenesis and tumor invasion of specific cancer cell 
lines are strongly reduced in PAI-1-deficient mice (53). Myofibroblasts 
located at the invasive front of colon cancer and malignant melanoma cells 
have been found to produce significantly higher amounts of PAI-1 than 
normal surrounding tissue (54). Inhibition of PAI-1 activity by antibodies or 
modulators, on the other hand, has been shown to suppress tumor cell 
invasion and angiogenesis in vitro (55). Elevated levels of both u-PA and 
PAI-1 are associated with poor prognosis in a variety of solid tumors. The 
elevation of u-PA and PAI-1 have been shown to have a significant impact 
on relapse-free and overall survival in patients with primary breast cancer 
(56). In addition, high levels of PAI-1 seem to be associated with preferential 
response to adjuvant chemotherapy, but relatively high resistance to 
hormone therapy in these patients (57). Expression of PAI-1 protein in tumor 
cells has also been described as a strong independent prognostic factor in 
cervical cancer (58) and in non-small cell lung carcinoma (59), and is also 
associated with a higher risk of relapse in squamous cell cancer of the oral 
cavity. 
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PAI-1 and type-2 diabetes 
 
Diabetes is a chronic metabolic disorder characterized by poor blood 
glucose control due to insulin deficiency (type 1) and/or insulin resistance 
(type-2) (60). Glucose is the primary fuel of cells. In healthy individuals, two 
principal glucose-regulating hormones, insulin and glucagon, maintain a 
constant glucose concentration in both the fasting and post-meal (post-
prandial) state. When blood glucose levels are high, such as after eating a 
meal, insulin is released. Produced by cells in the pancreas, called beta cells, 
it acts to encourage the uptake, utilization, and storage of glucose in muscle 
and fat tissues (adipose tissue), but mainly in the liver. During fasting, insulin 
output falls and a counter regulatory enzyme, glucagon, is released. Also 
produced in the pancreas, but by alpha cells, glucagon stimulates the 
release of glucose into the blood from the liver by breaking down glucose 
stores (called glycogen) and converting other fuel sources such as fats and 
proteins. In a healthy body, blood glucose levels rise and fall within a fairly 
tight range of 70-110 mg/dl. However, with diabetic insulin deficiency and/or 
resistance, blood glucose can rise to substantially higher concentrations, 
resulting in hyperglycaemia and, in the long term, causing blindness and 
damage to the kidney and heart, among other organs. There are two types 
of diabetes mellitus: 
 
A) In type 1 diabetes, or insulin-dependent diabetes, there is an absolute 
shortage of insulin resulting from destruction of the insulin-producing beta 
cells by the patient’s own immune system. Accounting for roughly 10% of 
cases, type 1 diabetes sufferers are typically young. Given type 1 patients’ 
inability to produce insulin, treatment inevitably includes supply of 
exogenous insulin. 
B) Type 2 diabetes accounts for roughly 90% of cases and occurs 
predominantly in people over 40. In over 60% of reported cases, patients are 
overweight. The disease is most often characterized by a resistance of the 
peripheral tissues to insulin, and impaired regulation of insulin secretion. 
Consequently, type 2 diabetes is also known as non-insulin dependent 
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diabetes mellitus (NIDDM); that is, insulin is produced but the body’s insulin 
receptors are insufficiently sensitive to its presence. As a result, the insulin-
producing beta cells over-compensate for this poor sensitivity, with the 
frequent result that, over time, they ‘burn out’. Hence, insulin production 
gradually deteriorates, with around 30% of patients eventually becoming 
insulin-dependent. 
 
In line with the observation by us and others that PAI-1 can induce insulin 
resistance by inhibiting the interaction between vitronectin and αvβ3 integrin 
(61, 62), it has recently been show that PAI-1 knock-out mice are resistant to 
high-fat-diet-induced insulin resistance (63, 64), indicating a role for PAI-1 in 
the pathogenesis of obesity-driven insulin resistance and hence T2DM. 
Moreover, levels of plasma PAI-1 have been shown to be a prognostic 
marker of T2DM independent of insulin resistance and other known risk 
factors for diabetes (65). In addition, plasma PAI-1 levels are elevated 
throughout the spectrum of insulin resistance, from the metabolic syndrome 
to prediabetes (period of impaired glucose tolerance) and to diabetes (66) 
(67) (68). Indeed, strategies that have been demonstrated to prevent 
diabetes, such as diet and exercise or administration of metformin or 
thiazolidinediones (TZDs) have also been shown to decrease plasma PAI-1 
concentrations (69) (70) (71) (72) (73). 
 
2.4 E2F transcription factor 
The E2F transcription factor is one of the key regulators of cell cycle events 
at the boundary of G0/G1 and S phases. E2F was originally defined as a 
cellular factor required for the adenovirus early region 1A (E1A)-transforming 
protein to mediate the transcriptional activation of the viral E2A promoter 
(74). The E2F consensus binding site is "TTTCGCGC," present in the 
adenovirus E2A promoter (74), and predominantly within the promoters of 
cellular genes required for cell division and apoptosis (75). Identified E2F 
target genes include cell cycle regulators such as cyclin E, cyclin A, cyclin 
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D1, Cdc2, and Cdc25A, enzymes involved in DNA synthesis such as 
dihydrofolate reductase (DHFR), DNA polymerase α, and thymidine kinase, 
and proteins essential for DNA replication, including Cdc6, ORC1, and the 
minichromosome maintenance (MCM) proteins (75). Apoptotic E2F target 
genes include apoptosis protease-activating factor 1 (Apaf1), p73, and ARF 
(76). 
E2F family 
In cells, E2F activity arises from a family of heterodimeric transcription 
factors, where each heterodimer consists of one member of the E2F family 
bound to a member of the DP family (75). In mammalian cells, six E2F family 
members have been identified (E2F-1 to E2F-6), while two members of the 
DP family, DP-1 and DP-2, have been characterized (Fig. 2.12). All possible 
combinations of E2F/DP complexes can exist in vitro, potentially allowing for 
the formation of an array of E2F complexes in cells (75). 
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Fig. 2.12. Structural comparison of E2F and DP family members. (A) 
The E2F family can be divided into three subgroups based on sequence 
homology. E2F-1, E2F-2, and E2F-3 represent one subgroup; E2F-4 and 
E2F-5 represent a second subgroup; and E2F-6 represents a third subgroup. 
The E2F-1 subgroup has an N-terminal cyclin/cdk binding site and a nuclear 
localization signal (NLS). E2F-4 and E2F-5 have truncated N-terminal 
regions and lack a cyclin/cdk binding site and an NLS, instead possessing a 
nuclear export signal (NES). The positions of pocket protein binding and 
transactivation domains are indicated. (B) Summary of DP-1 and DP-2 
family members. E2F and DP proteins share a conserved DNA binding and 
dimerization domain. Four alternatively spliced forms of DP-2, which are 
either cytoplasmic (β and γ) or nuclear (α and δ), have been described. The 
expression of specific DP proteins may influence E2F localization. 
 
The E2F family can be further divided into three subgroups based on 
sequence homology: E2F-1, E2F-2, and E2F-3 represent one subgroup; 
E2F-4 and E2F-5 represent a second subgroup; and E2F-6 is the third. 
Functional similarities are evident within each subgroup: E2F-1, E2F-2, and 
E2F-3 share an N-terminal cyclinA/cdk binding domain and a canonical 
basic nuclear localization signal (NLS), while both are absent in E2F-4 and 
E2F-5 (77). Moreover, E2F/DP heterodimers interact with pocket proteins 
with a specificity that is largely determined by the E2F component (75). E2F-
1, E2F-2, and E2F-3 preferentially associate with pRb, whereas E2F-4 and 
E2F-5 predominantly interact with p107 and p130 (75). E2F-6 acts 
principally as a transcriptional repressor in a distinct pocket protein-
independent manner (78). In fact, E2F-6 diverges considerably from the 
other E2F family members, sharing almost no homology outside the core 
DNA binding and dimerization domains, and possesses truncated C- and N-
terminal regions relative to those of the other E2F subgroups (78).  
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E2F-1, E2F-2, and E2F-3 
E2F-1, E2F-2, and E2F-3 activate E2F-responsive genes and drive cellular 
proliferation (79). Overexpression of each protein is sufficient to induce 
quiescent cells to re-enter the cell cycle (80-83), and dominant-negative 
mutants block S-phase entry (84). Furthermore, the combined ablation of 
E2F-1, E2F-2, and E2F-3 prevents entry into S phase (85), and their 
overexpression overrides the effects of growth inhibitory proteins, such as 
p16, p21, and p27, and cell cycle arrest induced by γ-irradiation, TGFβ, or 
dominant-negative cdk2 (82), (86). This ability is dependent on its 
dimerization, DNA-binding, and transactivation domains, suggesting that the 
induction of transcription of E2F target genes is required for S-phase entry 
(80, 87).  
E2F can become inactivated through pocket protein binding, which prevents 
the expression of target genes. This inactivation is primarily caused by 
masking the E2F activation domain, since the pocket protein binding domain 
is integrated with the activation domain, thereby making E2F unable to 
communicate with the basal transcriptional machinery. Using in vitro 
transcription and DNase footprinting assays, pRb has been shown to hinder 
the assembly of the transcription initiation complex (88). In addition, pRb is 
able to mediate active repression of E2F targets through nucleating the 
assembly of a dominantly acting repressor complex (89, 90). Once targeted 
to the promoter by E2F, pRb recruits proteins endowed with chromatin-
modifying activity, including HDACs, the histone methyltransferase (MTase) 
SUV39H1, human brahma (HBRM), and human brahma-related gene 1 
(BRG1): human homologues of the yeast SWI2/SNF2 proteins that possess 
nucleosome-remodeling activities (86). 
Contrary to the earlier belief that E2F1-3 are transcriptional activators and 
E2F4-5 are transcriptional repressors (91), our laboratory have previously 
demonstrated that E2F1-3 act as transcriptional repressors of the PAI-1 
gene in a cell type-independent manner (92), (93). Subsequently, other 
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groups have shown repressive effects of E2F1 (94), E2F2 (95), and E2F3 
(96) on other target genes. 
Role of E2F in differentiation 
E2F family members have also been implicated in the regulation of 
differentiation. A recent study demonstrated that repression of E2F-1/DP-1-
dependent transcription by the C/EBPα transcription factor is essential for 
cell cycle exit and the differentiation of adipocytes and neutrophil 
granulocytes in vivo (97). The importance of repressing E2F activity for the 
initiation of differentiation has also been observed in myogenic cells and in 
keratinocytes (98, 99), and loss of E2F repression through Rb mutation 
leads to uncontrolled proliferation and apoptosis in vivo (100, 101). While 
this highlights the role of both Rb and C/EBPα in the repression of E2F 
activity during development, C/EBPα can repress E2F in the absence of 
functional pRb protein (102, 103).This indicates that the C/EBPα and pRb 
pathways of E2F repression act independently. Moreover, in differentiating 
granulocytic cells p130, rather than pRb, has been found to be the critical 
pocket protein (103, 104), indicating that, in addition to E2F-1, repression of 
E2F4-5 is critical for proper differentiation of granulocytes (97).  
The differentiation of preadipocytes into adipocytes requires that growth-
arrested preadipocytes re-enter the cell cycle before undergoing terminal 
differentiation (105). In confluent preadipocytes, the E2F-4/p130 complex 
acts to repress the transcription of E2F target genes, including PPARγ, the 
master regulator of adipogenesis. Hormonal stimulation results in the loss of 
this repressive complex and the induction of activating E2Fs, particularly 
E2F-1. E2F-1 can directly activate PPARγ transcription, and thereby activate 
differentiation. Interestingly, during the late stages of differentiation the E2F-
4/p130 complex reforms, possibly to switch off PPARγ transcription in 
terminally differentiated adipocytes. 
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3. Research objective  
 
 
Fig. 3.1. Obesity and its secondary 
disorders. Obesity is known to lead 
to type-2 diabetes mellitus (T2DM), 
cardiovascular disorders (CVDs), and 
certain types of cancer. T2DM is also 
known to independently contribute to 
the development of CVD. 
 
 
The signaling defects that underlie the secondary complications of obesity, 
such as diabetes and cardiovascular complications, are well characterized. 
The ‘molecular signatures’ of diabetes and diabesity-induced 
cardiovascular complications are insulin resistance and inhibition of 
the glycolytic pathway, respectively. Now that the strong link between 
obesity and its secondary complications are well recognized, this leads to 
the key question of how does obesity lead to these signal transduction 
defects? Numerous molecules, including TNF-α, PAI-1, adiponectin, resistin, 
leptin, klotho, PPARγ, RBP4, MCP-1, IL-6, IL-1β, JNK, and superoxide 
anions, etc. have been reported to contribute to the obesity-driven 
pathologies. Although their levels are altered in obesity, none of these 
factors can account for all of the diverse signaling defects, nor has restoring 
the physiological status of any one of these factors been shown to be 
sufficient to prevent (although it may retard) secondary disorders in the 
obese. Taken together, it appears that obesity leads to multiple signaling 
disorders, although no convincing unifying mechanism as to how this 
happens has been proposed. 
 
In the first and second part of this study, we looked for nodal signal 
transduction points, whose potential dysfunction under conditions of 
obesity can activate pathological signaling implicated in T2DM and 
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cardiovascular complications. In the third part of our study, we studied 
the physiological regulation and pharmacological modulation of a 
common downstream mediator of these signal transduction defects.  
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4.1 Specific research objectives 
 
We looked for a unifying mechanism via which obesity would lead to the 
characteristic signaling defects that are associated with obesity-driven 
secondary disorders.  
 
It has been shown that obesity is accompanied by the reduction of two 
essential components of caveolae: cholesterol and caveolin-1/3. In this 
section, we investigated whether perturbation of a caveolar signal 
transduction platform would upset the physiological signaling and could lead 
to insulin resistance, the central feature of T2DM. We also sought to look at 
how insulin resistance regulates the gene expression of PAI-1, a critical 
mediator of cardiovascular complications. 
 
4.2 Abstract 
The levels of three integral components of caveolar microdomains, caveolin-
1, caveolin-3, and plasma membrane cholesterol, are reduced during 
conditions of obesity. Here we show that perturbation of caveolar 
microdomains leads to insulin resistance in cultured 3T3L1 adipocytes. This 
was accompanied by the upregulation of PAI-1 in a manner that correlates 
with the degree of insulin resistance. We present several lines of evidence 
showing that the phosphatidylinositol 3-kinase (PI3K) pathway negatively 
regulates PAI-1 gene expression. Insulin-induced PAI-1 gene expression is 
upregulated by a specific inhibitor of PI3K. In addition, serum PAI-1 levels 
are elevated in protein kinase Bα (PKBα)-deficient mice, while they are 
reduced in p70 ribosomal S6 kinase 1 (S6K1)-deficient mice. Using cell-
penetrating peptides that are homologous to the pRB binding region of E2F-
1, we could disrupt pRB-E2F interaction, and thereby release free E2F, a 
known transcriptional repressor of PAI-1. These peptides were able to 
suppress PAI-1 levels that are elevated during insulin-resistant conditions. 
This study identifies a caveolar-dependent signal pathway that upregulates 
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PAI-1 in insulin-resistant adipocytes, and proposes a novel pharmacological 
paradigm of disrupting pRB-E2F interaction to suppress PAI-1 levels. 
 
4.3 Introduction 
Type-2 diabetes mellitus (T2DM) is characterized by insulin resistance, 
where the insulin receptor fails to elicit the metabolic signaling that is 
required for glucose metabolism and energy homeostasis. In insulin-
sensitive tissues, the insulin receptor transduces two main signaling 
cascades: a metabolic signaling that is responsible for glucose uptake and 
glycogen synthesis; and a mitogenic signaling that is responsible for cell 
proliferation and growth. The IRS-PI3K-PKB and Cbl-CAP-Flotillin pathways 
represent the major metabolic signaling, while the Shc-Ras-Erk pathway 
represents the major mitogenic signaling (1). Both in animal models and 
clinical T2DM subjects, a selective impairment of metabolic signaling has 
been observed, while mitogenic signaling is more or less unaffected (2-4). 
 
Obesity is prominent among the plethora of factors that leads to the 
development of T2DM, although the molecular mechanism underlying the 
pathogenesis of obesity-driven T2DM is not well understood. Comparative 
analysis of large and small fat cells within the same fat pad reveals a two-
fold reduction in the levels of plasma membrane cholesterol in large fat cells, 
suggesting that a decrease in membrane cholesterol is characteristic of 
adipocyte hypertrophy per se (5). Recently, it has been proposed that the 
protein levels of caveolin-1 and caveolin-3 are inversely correlated to the 
body mass index (6). Plasma membrane cholesterol (7) and caveolins (8) 
are indispensable for the structural and functional integrity of caveolar 
microdomains. We therefore reasoned that obesity might lead to caveolar 
dysfunction. Since the insulin receptor and several of its downstream signal 
transducers are localized in caveolae (9), it was intriguing to investigate 
whether caveolar dysfunction could lead to insulin resistance.  
 
 46
There is compelling evidence that plasminogen activator inhibitor-1 (PAI-1), 
whose levels are elevated in both obesity and T2DM, plays an important role 
in the development of cardiovascular disorders (10). PAI-1, a primary 
physiological inhibitor of plasminogen activators (uPA and tPA), inhibits both 
fibrinolysis and proteolysis, and plays an important role in mediating the 
cardiovascular complications associated with T2DM, such as nephropathy 
(11), retinopathy (12), coronary artery disorders (13), and hypertension (14). 
Consequently, it is believed that normalizing plasma PAI-1 levels will retard 
the progression of cardiovascular complications (15). Insulin-induced Erk 
phosphorylation, followed by the activation of transcription factors of the AP-
1 family, is considered to be partly, if not wholly, responsible for the insulin-
induced PAI-1 upregulation in insulin-sensitive tissues (16, 17). However, 
because the mitogenic MAP kinase pathway is not affected during 
hyperinsulinemic conditions, such as insulin resistance or T2DM, this 
pathway is unlikely to be the primary cause of PAI-1 elevation during these 
pathological conditions. It is, therefore, intriguing to investigate whether 
insulin induction of PAI-1 during T2DM can be explained by directly linking 
the compromised PI3K pathway to PAI-1 upregulation. Interestingly, it has 
been shown that insulin receptor-mediated activation of metabolic signaling 
(PI3K pathway) induces the phosphorylation of retinoblastoma protein (pRB) 
in adipocytes (18). pRB phosphorylation is known to lead to the release of 
free E2F (19). We have previously demonstrated that E2F transcription 
factors can negatively regulate PAI-1 gene expression by repressing PAI-1 
promoter activity independently of its binding to pocket proteins, revealing a 
novel mechanism for the E2F-mediated repression of gene expression (20). 
In this study, we investigate whether caveolar dysfunction can lead to insulin 
resistance, and if the resulting impairment of the PI3K-PKB-E2F pathway 
can by itself lead to the upregulation of PAI-1. We also explore the 
pharmacological disruption of the E2F-pRB interaction in order to release 
free E2F, which we hypothesize will attenuate PAI-1 transcription and hence 
its plasma level. Adipocytes are chosen for this study as they are 
responsible for obesity, abundant in caveolae (21), highly sensitive to insulin 
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(over 200,000 receptors per cell) (22), the primary site for insulin resistance 
(23), and a major contributor of plasma PAI-1 in the obese (24). 
4.4 Materials and methods 
Reagents. MBCD and filipin III were obtained from Sigma. Monoclonal 
antibodies against E2F1 (KH-95) and E2F2 (TFE-25), and rabbit polyclonal 
antibodies against E2F3 (C-18), E2F4 (C-20), E2F5 (C-20), pRB (M-153), 
p130 (C-20), p107 (C-18), IRS-1 (C-20), Erk, and PAI-1 (H-135) were from 
Santa Cruz Biotechnology. Rabbit polyclonal antibodies against phospho-
pRB (Ser-795) and phospho-Erk were from Cell Signaling. Rabbit polyclonal 
antibodies against Shc and phospho-tyrosine (G410) were from 
Transduction Laboratories. Sheep polyclonal antibody against PAI-1 was 
from American Diagnostics. All reagents for real-time PCR were from 
Applied Biosystems. The oligonucleotide E2pro, the sequence of which 
corresponded to nucleotides -72 to -32 of the adenovirus E2 promoter and 
contained E2F binding sites, had the following sequence (only the upper 
strand is given) and was used for gel-shift assays: 5’-GAT CAG TTT TCG 
CGC TTA AAT TTG AGA AAG GGC GCG AAA CTA G-3’. 
 
Adipocyte differentiation. 3T3-L1 preadipocytes were cultured in DMEM 
containing 10% FCS, and 2 days after cells reached confluency the medium 
was changed to DMEM containing 10% FCS, 10 µg/ml insulin, 1 µM 
dexamethasone, and 0.5 mM isobutylmethylxanthine. 2-3 days later, this 
medium was replaced with DMEM supplemented only with 10 µg/ml insulin 
and cells were kept for 2 days. The medium was then replaced with DMEM 
containing 10% FCS every 2 days. The cells were serum starved overnight 
prior to experiments.  
 
Immunoprecipitation and Western blotting. Immunoprecipitation and 
Western blotting were performed as previously described (25). 
 
Glucose uptake assay. Measurements of 2-deoxyglucose uptake into 
adipocytes were carried out as previously described (26). 
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RNA isolation and Northern blot analysis. Total RNA (12 µg) was isolated 
and subjected to Northern blot analysis as described (27). The cDNA clone 
for mouse PAI-1 was provided by A. Riccio (University of Naples).  
 
Quantitative real-time PCR. One microgram of total RNA was reverse 
transcribed and 1 ul RT reaction was added to 24 ul PAI-1 PCR reaction 
(1×universal master mix, 900 nM forward primer [5'-
CCTGGCCGACTTCACAAGTC-3'], 900 nM reverse primer [5’-
TTGCAGTGCCTGTGCTACAGA-3'] and 200 nM TaqMan probe [5'-FAM-
TCCGACCAAGAGC-MGB-3']). Thermal cycling was done as follows: 50°C 
for 2 min, followed by 95°C for 10 min, and then 45 cycles of 95°C for 1 min 
and 60°C for 1 min. The fluorophor dyes for the PAI-1 probe and 18S rRNA 
(internal control) probe were FAM and VIC, respectively. The quencher in 
both probes was TAMRA. The reaction was carried out in an ABI Prism 7700. 
The output raw data was normalized with internal control, and statistically 
analyzed using MS Excel.  
 
siRNA nucleofection. siRNA used for targeting caveolin-1 mRNA has the 
following sequence: sense, 5'-GAGCUUCCUGAUUGAGAUU-3' and 
antisense, 5'-AAUCUCAAUCAGGAAGCUC-3'. Control siRNA sequences: 
sense, 5'-GUACCUGACUAGUCGCAGAAG-3' and antisense, 5'-
UCUGCGACUAGUCAGGUACGG-3'. These sequences contain 3' UU 
overhangs. Specificities of these sequences were confirmed by performing a 
BLAST search against the GenBank/EMBL database. Each siRNA (final 
concentration 1 µM) was mixed with NIH-IR cell suspension (2x106 cells in 
0.1 ml buffer-T/transfection), transferred to a 2-mm electroporation cuvette, 
and electroporated using an Amaxa Nucleofector™ (Amaxa, Germany) 
using program A-23. After electroporation, cells were immediately 
transferred to 1 ml growth medium, and cultured in 6-well plates at 37°C until 
analysis. 
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S6K1-/- and PKBβ-/- mice. PKBα knock-out mice were generated as 
previously described (28). S6K1 knock-out mice (29) were kindly provided by 
G. Thomas (FMI, Switzerland). The S6K1-/- mice and their wildtype 
counterparts were fed with a high-fat diet for 5-6 months (required for 
hyperactivity of the PI3K pathway) before their blood was taken using tail 
punctures. PKBα-/- mice were fed with normal chow diet. 
 
Cell-penetrating peptide treatment. The sequence of the interfering 
peptide of 18 aa-length was derived from the pRB-binding region of E2F1 
(aa 402-419: LDYHFGLEEGEGIRDLFD) (30). A control peptide with the 
same amino acid composition, GEELEGFHDGLLDFDIR, was prepared by 
randomly shuffling the sequence of this peptide. Cell-penetrating peptides 
were prepared by coupling these peptides to the carboxyl terminal of the 
cell-penetrating region of the HIV tat protein (aa 47-57: RRRQRRKKR) (31) 
via hinge peptide G. Differentiated adipocytes were separated from 
undifferentiated cells using a Percoll density gradient as previously 
described (32), with a slight modification. Adipocytes were pre-treated with 
collagenase (2 mg/ml) for 30 min, centrifuged at 1,500 rpm for 5 min at 4°C, 
and mixed with Percoll solution (1.025 g/ml) to form a homogenous 
suspension. The cell suspension was then layered on preformed Percoll 
solution (1.035 g/ml) and centrifuged at 3,000 rpm for 20 min at 4°C. The 
cells collected from the upper layer were resuspended in media and 
reseeded for the experiment. The penetrating peptide was then added to 
cells, incubated for 16 h, and then subjected to various treatments. 
 
Nuclear extracts and electromobility shift assays. Nuclear extracts (5 µg) 
were first incubated at room temperature for 15 min in 20 µl binding reaction 
mixture containing 50 mM KCl, 20 mM HEPES (pH 7.9), 0.2 mM EDTA, 6% 
glycerol, 0.5% Ficoll 400, 1 µg salmon sperm DNA, 6 µg bovine serum 
albumin, and 1 mM DTT with or without penetrating peptide and antibodies, 
followed by a further 15-min incubation after addition of 0.3 ng radiolabeled 
oligonucleotide probes. Oligonucleotide probes were radiolabeled using E. 
coli polynucleotide kinase and [γ-32P]ATP. Aliquots (5 µl) of reaction mixture 
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were separated in a 4.5% polyacrylamide gel run in 0.25×TBE buffer at room 
temperature. The gel was dried and analyzed in a PhosphorImager. 
 
4.5 Results 
Perturbation of caveolar function mimics insulin resistance in 3T3L1 
adipocytes 
 
Fig. 4.1. Effect of cholesterol depletion on insulin signaling. 3T3L1 
adipocytes were treated with 0, 4 or 8 mM MBCD for 40 min, followed by 
insulin treatment (100 nM) for 10 min, and then whole cell extracts were 
prepared. The cell lysates were fractionated by SDS-PAGE, followed by 
Western blotting analysis using the specific antibodies indicated. For the 
analysis of IRS-1 and Shc, the lysates were first immunoprecipitated using 
IRS-1 and Shc antibodies, respectively, before Western blotting. (A) Analysis 
of PKB and IRS-1, molecules involved in the metabolic signal pathway. (B) 
Analysis of the insulin receptor (IR) and its mitogenic signal transducers Shc 
and Erk. (C) Effect of MBCD on insulin-induced glucose uptake. Adipocytes 
were treated similarly as above and then subjected to a glucose uptake 
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assay. All data shown here are representative of at least three independent 
experiments. 
 
To find out if caveolar dysfunction can cause insulin resistance, we 
perturbed the integrity of caveolar microdomains and examined the 
subsequent effects on insulin signaling. Cholesterol depletion using methyl-β 
cyclodextrin (MBCD), a reagent widely used to perturb the structural integrity 
of caveolae, was employed. MBCD pretreatment dose-dependently inhibited 
insulin-induced IRS-1 phosphorylation, PKB phosphorylation (Fig. 1A), and 
2-deoxyglucose uptake (Fig. 1C). On the other hand, MBCD pretreatment 
did not affect insulin-induced phosphorylation of the β-subunit of the insulin 
receptor, Shc, or Erk (Fig. 4.1B). MBCD treatment alone (in the absence of 
insulin) was also found to increase the phosphorylation of p52 Shc and Erk-
1/2, although to a lesser extent (Fig. 4.1B). 
 
Induction of insulin resistance leads to concomitant increase in PAI-1 
gene expression 
 
Fig. 4.2. Effect of caveolar dysfunction on insulin-induced PAI-1 mRNA 
levels. (A) Effect of MBCD on insulin-induced PAI-1 mRNA levels. 3T3L1 
adipocyte cells were treated with 0, 4, or 8 mM MBCD for 40 min, with or 
without subsequent insulin treatment (100 nM) for 2 h. The total RNA was 
prepared and PAI-1 mRNA levels were measured using real-time PCR with 
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18S rRNA as an internal control. (B) Effect of filipin on insulin-induced PAI-1 
mRNA levels. Adipocytes were treated with filipin (5 µg/ml) for 40 min, with 
or without subsequent 2 h insulin (100 nM) treatment. Total RNA was 
analysed as above. (C) Northern and Western blotting analysis. The RNA 
samples used in Fig. 4.2A were subjected to Northern blot hybridization 
analysis for PAI-1 mRNA levels. For the analysis of PAI-1 protein levels, 
cells were treated with 0, 4, or 8 mM MBCD for 40 min, followed by insulin 
(100 nM) treatment for 6 h. Then, PAI-1 protein was immunoprecipitated 
from the conditioned media (as PAI-1 is a secreted protein) using protein-G 
beads coupled to sheep anti-PAI-1 antibodies, and analyzed by Western 
blotting using rabbit anti-PAI-1 antibodies. (D, E) Effects of caveolin 
downregulation. NIH-IR cells were electroporated using buffer without siRNA, 
or with Cav-1 or control siRNA. After 24 h, the cells were treated with insulin 
(100 nM) for 2 h. Protein levels of caveolin-1, Erk, and β-tubulin (D) and 
mRNA levels of PAI-1 (E) were examined by Western blotting and RT-PCR, 
respectively. 
 
To determine whether MBCD-induced insulin resistance leads to the 
upregulation of insulin-induced PAI-1 gene expression, we measured PAI-1 
mRNA levels after insulin treatment with or without MBCD pretreatment. 
Results from both real-time PCR (Fig. 4.2A) and Northern blot hybridization 
(Fig. 4.2C) show that MBCD dose-dependently increased insulin-induced 
PAI-1 levels. To find out if this increase at the mRNA level is reflected at the 
protein level, PAI-1 protein levels were measured in the media. 
Corresponding to the mRNA levels, insulin-induced PAI-1 protein levels 
were dose-dependently upregulated by MBCD treatment. Filipin, a 
structurally distinct sterol-binding compound also augmented the insulin-
induced PAI-1 levels (Fig. 4.2B), suggesting that the observed MBCD effects 
were through perturbation of caveolae function per se. Figs. 2A and 2B 
clearly show that the effect of cholesterol depletion synergistically 
upregulated insulin-induced PAI-1 gene expression. To ascertain that the 
upregulation of PAI-1 observed here is due to caveolar dysfunction and not 
due to an unspecific effect of cholesterol depletion, we depleted the 
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caveolin-1 protein using siRNA directed against caveolin-1 mRNA. In this 
experiment, NIH3T3 cells over-expressing the human insulin receptor (NIH-
IR) were used instead of adipocytes, which proved difficult to transfect 
efficiently with siRNA. NIH-IR cells were chosen as the suitable alternative to 
adipocytes, as they are insulin-sensitive, rich in caveolae, share a common 
cell-lineage with adipocytes, and can be differentiated into adipocytes (33). 
This siRNA showed specific effects, as it significantly lowered the caveolin-1 
protein levels but did not affect levels of other proteins such as Erk or β-
tubulin (Fig. 4.2D). Furthermore, control siRNA had no effect on any of these 
proteins. Caveolin-1 siRNA treatment enhanced the levels of insulin-induced 
PAI-1 five-fold, whereas control siRNA had no significant effect (Fig. 4.2E). 
 
Impairment of PI3K pathway leads to transcriptional upregulation of 
PAI-1 
 
 
Fig. 4.3. The role of the PI3K pathway in PAI-1 gene expression. (A) 
Serum PAI-1 levels of PKBα-/- and S6K1-/- mice, and their wildtype 
counterparts were analyzed by PAI-1 immunoprecipitation followed by 
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Western blotting. The membranes were stained with Ponceau S for loading 
control. (B) 3T3L1 adipocytes were treated with LY294002 (30 µM) for 45 
min, followed by insulin (100 nM) for 2 h. Total RNA was prepared and 
analyzed for levels of PAI-1 and GAPDH (loading control) mRNAs by 
Northern blot hybridization. (C) 3T3L1 adipocytes were treated with 
increasing concentrations of either LY294002 or MBCD for 45 min, followed 
by insulin (100 nM) for 2 h, and the phosphorylation status of pRB and the 
protein levels of β-tubulin (loading control) were measured by Western 
blotting. 
 
To see if the upregulation of insulin-induced PAI-1 by caveolar dysfunction 
was a direct consequence of impaired metabolic signaling (PI3K pathway), 
we examined the levels of plasma PAI-1 in two different mouse models that 
are hallmarked by augmented (S6K1-/-) and attenuated (PKBα-/-) metabolic 
signaling. Activated S6K1 phosphorylates IRS-1 at serine residues and 
suppresses its tyrosine phosphorylation by the insulin receptor. Thus, 
deletion of S6K1 augments PI3K signaling in these mice (34). On the other 
hand, PKB is a critical mediator of PI3K signaling. Thus, deletion of PKB 
would attenuate the PI3K signal pathway. As shown in Fig. 4.3A, plasma 
PAI-1 levels were upregulated in PKBα-/- mice, while they were 
downregulated in S6K1-/- mice. The negative regulation of PAI-1 gene 
expression by the PI3K pathway was further confirmed in adipocyte cell 
culture, where the PI3K inhibitor (LY294002) enhanced insulin-induced PAI-
1 mRNA levels (Fig. 4.3B). Treatment with LY294002 and MBCD, both 
shown to inhibit the PI3K pathway, dose-dependently inhibited insulin-
induced pRB phosphorylation (Fig. 4.3C), thus providing a possible 
explanation of why PI3K pathway activation leads to the downregulation of 
PAI-1 gene expression (see below).   
 
Disruption of pRB-E2F interaction using a cell-penetrating peptide 
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Fig. 4.4. Effect of cell-penetrating, interfering peptide on free E2F levels. 
(A) In DNA gel-shift assays using 32P-labelled E2pro oligonucleotide and 
nuclear extracts from adipocytes, cell-penetrating peptide (specific and 
control peptides) was added to binding reactions at increasing 
concentrations. (B) Nuclear extracts (day 8) were preincubated with the cell-
penetrating, interfering peptide, together with specific antibodies against 
different E2F members, for 15 min, and then analyzed for E2F DNA-binding 
activity by gel-shift assays as above. 
 
Hypophosphorylated pRB is bound to E2F forming an inactive complex, 
while hyperphosphorylation of pRB leads to the release of free E2F (19). We 
have previously shown that overexpression of E2F isoforms can 
downregulate PAI-1 gene expression (20). It has also been shown that 
active pRB, which can bind to E2F, reverses this downregulation (27). Taken 
together, these results suggest that free E2F acts as a transcriptional 
repressor of the PAI-1 gene. We have observed that pRB phosphorylation is 
increased, while E2F-1 protein levels are reduced during adipogenesis (data 
not shown), suggesting that E2F activity (corresponding to free E2F) may be 
compromised in differentiated adipocytes. In order to restore the potential of 
E2F-mediated transcriptional repression of the PAI-1 gene in adipocytes, we 
sought to release free E2F by disrupting the E2F-pRB complex using an 
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interfering peptide that corresponds to amino acids 402-419 of E2F-1, the 
domain interacting with the pocket proteins (30). A BLAST search revealed 
that this domain is fairly conserved among members of the E2F family 
(excluding E2F-6) and, therefore, the peptide that we designed may disrupt 
the pocket protein-E2F interaction in general. As a control, we used a 
peptide with a randomly shuffled sequence. To render these peptides cell-
penetrable, an HIV-1 Tat-derived peptide sequence was tagged to these 
peptides (31). Avidity of these peptides to disrupt the E2F-pRB complex was 
confirmed by DNA-gel shift assays using adipocyte nuclear extracts and a 
radioactive oligonucleotide, the sequence of which corresponds to the E2F-
binding site of the adenovirus E2 promoter. As shown in Fig. 4.4A, DNA-
protein complexes shifted to low-molecular-weight forms when increasing 
concentrations of the specific peptide were added to binding mixtures; the 
control peptide had no effect. Supershift assays using specific antibodies 
against E2F1-5 revealed that the main isoforms in the freed E2F fractions 
were E2F-3, -4, and -5 (Fig. 4.4B). These peptides thus serve as an effective 
tool to disrupt endogenous E2F-pRB interactions. 
 
Elevation of PAI-1 levels in insulin-resistance is suppressed by the 
cell-penetrating peptide  
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Fig. 4.5. Effect of cell-penetrating, interfering peptide on PAI-1 mRNA 
levels. (A) Dose response of the peptides. 3T3L1 adipocytes (day 8) were 
treated with increasing concentrations (0-40 µM) of either specific or control 
peptide for 6 h, followed by treatment with or without 1 µM insulin for 2 h. 
Total RNA was prepared and levels of PAI-1 and GAPDH (loading control) 
mRNAs were measured by Northern blot hybridization. Ribosomal RNAs 
were stained with methylene blue to serve as an additional control for equal 
loading and blotting. (B) Effect of the peptides on PAI-1 mRNA levels, which 
are elevated under insulin-resistant conditions. Cells were serum starved 
and then treated with 40 µM of specific or control peptides for 12 h. Cells 
were then treated with MBCD for 40 min, followed by insulin (100 nM) for 2 h. 
Total RNA was prepared and analyzed for PAI-1 mRNA as above.   
 
To examine if interfering peptide treatment can compromise induction of 
PAI-1 by hyperinsulinemia and insulin resistance, we performed the 
following experiments. Adipocytes were prepared according to Materials and 
methods and were treated with either the specific or control peptide for 12 h, 
followed by 1 µM insulin for 2 h. As shown in Fig. 4.5A, the specific peptide, 
but not the control peptide, suppressed both basal and insulin-induced PAI-1 
levels in a dose-dependent manner, the latter being more potently affected 
(Fig. 4.5A). Furthermore, the specific peptide also suppressed PAI-1 
expression that was upregulated by MBCD-induced insulin resistance (Fig. 
4.5B). Again, the control peptide had no effect.  
 
4.6 Discussion 
Obesity is characterized by increased adipocyte mass and altered adipocyte 
physiology. These traits contribute towards the progression from obesity to 
insulin resistance (35). Reductions in plasma membrane cholesterol and 
protein levels of caveolin-1/3 are associated with adipocyte hypertrophy and 
obesity, respectively (5, 6). It is thought that this could lead to caveolar 
 58
dysfunction, because plasma membrane cholesterol and caveolin are 
essential for the structural and functional integrity of caveolae (7, 8). To 
study the acute effects of caveolar dysfunction in adipocytes, we employed 
cholesterol-scavenging reagents, such as MBCD, which are known to 
perturb caveolae in adipocytes (36). Kinetic studies have suggested that the 
vast majority of cholesterol scavenged by cyclodextrins is from the plasma 
membrane (37), where more than 90% of cellular cholesterol is known to 
reside (38). Treatment with MBCD did not affect insulin-induced tyrosine 
phosphorylation of the insulin receptor and its downstream mitogenic 
signaling, but impaired the IRS-PKB signal pathway that leads to glucose 
uptake (Figs. 1A and B). This suggests that cholesterol depletion and, 
presumably, consequent caveolar dysfunction would lead to insulin 
resistance. Consistently, it was recently reported that caveolin-1-/- and 
caveolin-3-/- mice, both known to have a dramatic reduction in caveolae, 
exhibit insulin resistance (39, 40). Moreover, in adipocytes treated with 
TNFα, the insulin receptor accumulated less in the detergent-insoluble low-
density membrane fractions (microdomains), and shifted to the high-density 
fractions, indicating a translocation of insulin receptor from caveolar to non-
caveolar fractions (41). TNFα is a potent inducer of insulin resistance (42) 
and PAI-1 gene expression (43). It is chronically elevated in conditions of 
obesity and is a major culprit in the pathogenesis of obesity-driven insulin 
resistance (42). Thus, denying the caveolar platform for insulin receptor 
signaling could be a plausible mechanism through which obesity per se, and 
its secondary effectors, elicit insulin resistance. Our hypothesis warrants 
further investigations into the structural and functional integrity of caveolae in 
obese and T2DM patients.  
 
Treatment of adipocytes with two structurally distinct cholesterol-depleting 
reagents (MBCD and filipin) leads to upregulation of insulin-induced 
expression of PAI-1 mRNA and protein levels (Figs. 2A, B, and C). Similar 
upregulation is also obtained in NIH-IR cells after RNAi-mediated caveolin-1 
downregulation (Fig. 4.2E). Thus, perturbation of caveolae by depleting their 
integral components, either cholesterol or caveolin-1, leads to significant 
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upregulation of insulin-induced PAI-1 gene expression. MBCD alone induces 
PAI-1 mRNA to a certain extent (Fig. 4.2), but this level of induction can be 
explained by a slight activation of Erk, as Erk has been reported to 
upregulate the PAI-1 gene by activating the AP-1 transcription factor (44). 
However, the MBCD-mediated synergistic increase in insulin-induced PAI-1 
gene expression cannot be explained by Erk activation, as the extent of 
insulin-induced Erk phosphorylation (Fig. 4.1B) was not affected by MBCD 
co-treatment. We therefore postulate an alternative mechanism for the 
upregulation of insulin-induced PAI-1 gene expression mediated by caveolar 
dysfunction (see below).  
 
Insulin-induced PAI-1 mRNA levels are augmented by treatment with a 
specific PI3K inhibitor, suggesting that the PI3K pathway inhibits PAI-1 gene 
expression (Fig. 4.3B). We show that the level of serum PAI-1 is increased 
in PKBα-/- mice, while it is reduced in S6K1-/- mice (Fig. 4.3A). The whole 
blood protein concentration in both PKBα-/- and S6K1-/- is similar to that of 
their wildtype littermates. These results indicate that the functional state of 
the PI3K pathway plays an important role in the regulation of PAI-1 gene 
expression. 
 
There are several reports of the PI3K pathway regulating pRB-E2F 
interactions in a cell-type independent manner. Activation of PKB by 
inhibition of its phosphatases reduced the pRB phosphorylation and E2F1 
release in C141 cells (45). In T lymphocytes, expression of active PKB is 
sufficient to induce E2F activity (46). In C33A cells, both wortmannin (PI3K 
inhibitor) treatment and overexpression of PTEN (a negative regulator of the 
PI3K-PKB pathway) inhibited pRB phosphorylation, and this was reversed 
by co-expression of a catalytically active subunit of PI3K (47). In NIH3T3 
fibroblasts, EGF-induced pRB phosphorylation, and hence G1 to S phase 
cell cycle progression, was inhibited by both LY294002 and wortmannin 
(48). In agreement with the finding of Usui et al. (18), we show that 
LY294002 inhibits insulin-induced phosphorylation of pRB in 3T3L1 
adipocytes. MBCD also shows similar effects (Fig. 4.3C), implying that 
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impaired metabolic signaling, characteristic of insulin resistance, may reduce 
the phosphorylation of pRB. Hypophosphorylated pRB is known to bind 
E2F1-3 proteins, and inhibits their activity, either by directly binding to and 
masking the transactivation domain of E2F, or by recruiting histone 
deacetylases (19). Reduction in pRB phosphorylation, therefore, will result in 
the reduction of free E2F levels. We have previously shown that free E2F 
can act as a repressor of PAI-1 gene expression in a variety of cell lines, 
including U2OS, T98G, SAOS2, LLC-PK1, and MEF cells, indicating that the 
E2F-mediated negative regulation of PAI-1 gene expression is a general 
phenomenon independent of cell type (27). Taking these observations 
together, we propose that the PI3K pathway in insulin signaling negatively 
regulates the PAI-1 gene, and phosphorylation of pRB and subsequent 
release of free E2F may play a role. This, in essence, is indicative of 
differential regulation of PAI-1 gene expression by insulin; positive regulation 
through the mitogenic pathway and negative regulation through the 
metabolic pathway. The compromised metabolic pathway may explain why 
insulin-induced PAI-1 levels are upregulated in states of caveolar 
dysfunction.  
 
It is widely accepted that PAI-1 levels are raised in conditions of obesity and 
insulin resistance (10), and they play a key role in the development of 
cardiovascular complications in these patients. Recent studies show that 
PAI-1 knock-out mice are resistant to high-fat diet-induced obesity and 
insulin resistance, although the underlying molecular mechanisms are not 
well understood (49, 50). In line with the data from Vuori et al. (51) showing 
that vitronectin-αvβ3 integrin interaction facilitates insulin-induced IRS-1 
activation, we had earlier proposed a model in which PAI-1 can induce 
insulin-resistance by binding to vitronectin and inhibiting its interaction with 
αvβ3 integrin (52). This suggests that PAI-1 can be a cause as well as a 
consequence of insulin resistance, and reducing its levels may offer 
immense therapeutic value. Both basal and insulin-induced PAI-1 levels 
could be dramatically reduced by treating adipocytes with a cell-penetrating 
peptide that physically disrupts the pRB-E2F interaction (Fig. 4.5A). 
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Furthermore, the interfering peptide was also able to suppress the elevation 
of PAI-1 mRNA levels in insulin-resistant adipocytes (Fig. 4.5B). These 
results strengthen our previous findings that E2F proteins can act as a 
transcriptional repressor of the PAI-1 gene.  
 
In summary, we have demonstrated that caveolar dysfunction leads to the 
selective impairment of the PI3K pathway in adipocytes. This compromises 
E2F-mediated suppression of PAI-1 gene expression, resulting in the 
concomitant upregulation of PAI-1 levels. Our work thus establishes a direct 
link between an impaired PI3K pathway and elevated PAI-1 gene 
expression, both characteristics of insulin-resistant conditions. We also 
propose a novel pharmacological paradigm of disrupting pRB-E2F 
interaction to suppress PAI-1 levels that are elevated during insulin 
resistance. Recently, the crystal structure of E2F bound to pRB was solved 
(53), and this should facilitate the development of small molecule inhibitors 
of E2F-pRB interaction. 
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4.7 Working Model 
  
 
 
Working model: Under normal conditions, insulin receptor localized in the 
caveolar microdomains activates two major pathways. The mitogenic 
signaling (Shc-Erk pathway) upregulates PAI-1 gene expression, while the 
metabolic pathway (IRS-PKB) pathway downregulates PAI-1 gene 
expression. Destruction of caveolar microdomains selectively abrogates the 
metabolic signaling leading to insulin resistance. Based on other studies, we 
reason that under obese conditions and TNF-α treatment, the insulin 
receptor might not localize in caveolae, thereby indicating that caveolar 
dysfunction might be a natural cause of insulin resistance in obese 
conditions. Insulin resistance abolishes the inhibitory signal to the PAI-1 
promoter, and thereby enhances PAI-1 gene expression. However, PAI-1 
gene expression under insulin-resistant conditions can be effectively 
suppressed by the release of endogenous free E2F, previously 
demonstrated by us to be a transcriptional repressor of PAI-1 gene 
expression. 
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5.1 Specific research objectives 
In the previous section, we showed that perturbation of caveolar 
microdomains leads to insulin resistance (characteristic feature of T2DM) in 
adipocytes. Obesity and T2DM are accompanied by increased oxidative 
stress mediated by enhanced mitochondrial superoxide anion production. It 
is now believed that the vascular complications in diabetic patients are a 
result of hyper-glycemica induced oxidative stress, which leads to the 
inhibition of glycolysis followed by activation of four pathways (Protein 
Kinase C pathway, Polyol pathway, AGE pathway and Hexosamine 
pathway). In this section we investigated if caveolar dysfunction can also 
lead to this central signaling defect considered to be responsible for the 
vascular complications associated with obesity and diabetes. This is 
particularly intriguing since the caveolin-1 deficient mice demonstrate severe 
vascular abnormalities. 
 
 
5.2 Abstract 
We show that three glycolytic enzymes, fructose-biphosphate aldolase, 
glyceraldehyde-3 phosphate and phosphoglycerate kinase-1, bind to 
caveolin-1. This novel finding is supportive of work from other laboratories 
that suggests that membrane-associated glycolysis may happen in the 
caveolar microdomain. Additionally, we show that the perturbation of 
caveolar microdomains using cyclodextrin leads to the activation of the PKC 
pathway, hexosamine pathway, and PAI-1 gene expression presumably by 
the inhibition of glycolysis and the diversion of glycolytic intermediates from 
these pathways. 
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5.3 Introduction 
Obesity and diabetes are independent risk factors of cardiovascular 
complications. Diabetes-specific microvascular disease is a leading cause of 
blindness (retinopathy), renal failure (nephropathy) and nerve damage 
(neuropathy), cardiac problems (atherosclerosis, myocardial infarction), 
stroke and limb amputation [Vaughan, 2003 #552]. It is believed that the 
increased superoxide anion production is the main culprit in mediating these 
disorders. Diabetic hyperglycemia is the main inducer of superoxide anion 
production and current efforts towards the clinical management of diabetes 
is focused on the control of blood sugar level.  
 
 
Increased superoxide production 
 
Fig. 5.1. Potential mechanism by which hyperglycaemia-induced 
mitochondrial superoxide overproduction activates four pathways of 
hyperglycaemic damage. Increased oxidative stress leads to the inhibition 
of GAPDH, hence glycolysis. This then leads to the diversion of glycolytic 
intermediates to 4 pathways that are implicated in vascular damage. (Figure 
courtesy: Brownlee M, 2001, Nature) 
 
 
 
 70
How does hyperglycemia lead to increased superoxide production? 
Studies in cell-culture, animal models, and in clinical subjects have 
implicated four main molecular mechanisms mediating hyperglycemia-
induced vascular damage [Brownlee, 2001 #571]. As shown in the Fig-1, the 
four pathways are the increased polyol pathway flux; increased advanced 
glycation end-product (AGE) formation; activation of protein kinase C (PKC) 
isoforms; and increased hexosamine pathway flux. All seem to reflect a 
single hyperglycaemia-induced process of overproduction of superoxide by 
the mitochondrial electron-transport chain.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2 Over production of superoxide by hyperglycemia (Figure 
courtesy: Brownlee M, 2001, Nature) 
 
There are four protein complexes in the mitochondrial electron transport 
chain, called complex I, II, III, and IV (Fig. 5.2). When glucose is metabolized 
through the tricarboxylic acid (TCA) cycle, it generates electron donors. The 
main electron donor is NADH, which gives electrons to complex I. The other 
electron donor generated by the TCA cycle is FADH2, formed by succinate 
dehydrogenase, which donates electrons to complex II. Electrons from both 
these complexes are passed to coenzyme Q, and then from coenzyme Q 
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they are transferred to complex III, cytochrome-C, complex IV, and finally to 
molecular oxygen, which they reduce to water. In normal cells, the electron 
transport system is organized in this way so that the level of ATP can be 
precisely regulated. As electrons are transported from left to right in Fig. 5.2, 
some of the energy of those electrons is used to pump protons across the 
membrane at complexes I, III, and IV. This generates a potential difference 
across the mitochondrial membrane. The energy from this voltage gradient 
drives the synthesis of ATP by ATP synthase [Mitchell, 1976 Biochem Soc 
Trans 4:399-430; Wallace, 1992 #2308; Trumpower, 1990 #2309]. 
Alternatively, uncoupling proteins (UCPs; Fig. 5.2) can divert the energy 
from the voltage gradient to heat production as a way of keeping the rate of 
ATP generation constant.  
In contrast, in diabetic cells with high internal glucose concentrations, there 
is more glucose being oxidized by glycolysis [glucose is not a substrate of 
the TCA cycle, pyruvate/acetyl-CoA is], which pushes more NADH and 
FADH2 into the electron transport chain. As a result, the potential difference 
across the mitochondrial membrane increases until a critical threshold is 
reached. At this point, electron transfer inside complex III is blocked 
[Korshunov, 1997 #2310], causing the electrons to back up to coenzyme Q, 
which donates the electrons one at a time to molecular oxygen, thereby 
generating superoxide (Fig. 5.2). The mitochondrial isoform of the enzyme 
superoxide dismutase degrades this oxygen free radical to hydrogen 
peroxide, which is then converted into H2O and O2 by hydrogen peroxidase.  
This theory is supported by the following experiments. Intracellular 
hyperglycemia was found to increase the voltage across the mitochondrial 
membrane above the critical threshold necessary to increase superoxide 
formation [Du, 2001 #2311]. Not surprisingly, this led to a significant 
increase in production of ROS. In contrast, an identical level of 
hyperglycemia does not increase ROS at all in cells overexpressing UCP, 
where the mitochondrial voltage gradient is reduced [Nishikawa, 2000 
#2312]. Similarly, hyperglycemia does not increase ROS in cells 
overexpressing superoxide dismutase (MnSOD), a scavenger of superoxide. 
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These data demonstrate two things. Firstly, the UCP effect shows that the 
mitochondrial electron transport chain is the source of the hyperglycemia-
induced superoxide. Secondly, the MnSOD effect shows that the initial ROS 
formed is indeed superoxide. Furthermore, in 0 endothelial cells (cells 
depleted of mitochondrial genes), which lack a functional mitochondrial 
electron transport chain the effect of hyperglycemia on ROS production as 
well as subsequent activation of the polyol pathway, AGE formation, PKC, or 
the hexosamine pathway is completely lost [Brownlee, 2005 #2313]. 
 
These results have been confirmed by in vivo experiments. When wild-type 
animals are made diabetic, all four of the pathways are activated in tissues 
where diabetic complications occur. In contrast, when MnSOD transgenic 
mice are made diabetic, there is no activation of any of the four pathways. 
Importantly, inhibition of hyperglycemia-induced superoxide overproduction 
using a transgenic approach (superoxide dismutase [SOD]) also prevents 
secondary complications of diabetes including long-term experimental 
diabetic nephropathy [DeRubertis, 2004 #2314].  
 
How does obesity lead to increased superoxide production? 
 
Recent studies have demonstrated that, in non-diabetic human subjects, fat 
accumulation is closely correlated with the markers of systemic oxidative 
stress [Furukawa, 2004 #2335]. These data are in good agreement with 
recent studies suggesting that systemic oxidative stress correlates with BMI 
[Keaney, 2003 #2347; Sinaiko, 2005 #2349]. Moreover, the production of 
reactive oxygen species was shown to be upregulated during 3T3L1 
adipocyte differentiation. Studies using murine models of obesity indicate 
that the increased ROS production is restricted to white adipose tissue and 
is mediated by both NADPH oxidase upregulation and SOD downregulation 
[Furukawa, 2004 #2335; Sonta, 2004 #2351].  
 
How does activation of the four pathways lead to the cardiovascular 
complications? 
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The precise mechanism via which the four pathways may contribute to 
cardiovascular events is discussed elsewhere [Brownlee, 2001 #571]. The 
graphical representations of the mechanisms are presented below. Notably, 
increase in the PAI-1 gene expression is a common mechanism via which at 
least two out of four pathways (glucosamine and PKC) elicit cardiovascular 
damage [Du, 2001 #2311] [Suzuki, 2002 #2350].  
 
 
 
 
 
 
 
 
 
 
Fig. 5.3 Mechanisms contributing to the PKC-induced damage. 
Upregulation of PAI-1 is contributing factor. (Figure courtesy: Brownlee M, 
2001, Nature) 
 
I 
Fig. 5.4 Mechanisms 
contributing to the 
glucosamine-induced 
damage. Glucosamine 
pathway can lead to an 
increase in glycosylation of 
SPI-1 transcription factors 
leading to enhanced 
expression of PAI-1and TGF-β. 
(Figure courtesy: Brownlee M, 
2001, Nature) 
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Fig. 5.5 Mechanisms 
contributing to the 
AGE-induced 
damage. (Figure 
courtesy: Brownlee M, 
2001, Nature) 
 
 
 
 
 
 
Fig. 5.6 Mechanisms 
contributing to the 
polyolpathway-induced 
damage. (Figure courtesy: 
Brownlee M, 2001, Nature) 
 
 
 
The hypothesis outlined above is considered by many to be the holy-grail of 
diabesity induced-vascular complications. Our studies propose caveolar 
dysfunction to be an inducer of insulin resistance in obese patients and 
recent studies implicate a role for caveolin down regulation in increased cell 
proliferation. Therefore it is intriguing to investigate if caveolar dysfunction 
can also activate pathways that are responsible for cardiovascular 
complications. If yes, then caveolar dysfunction could be considered to be 
the unifying mechanism by which obesity elicits its secondary disorders such 
as type-2 diabetes, cardiovascular complications and certain types of cancer. 
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5.4 Materials and methods  
Adipocyte differentiation. 3T3-L1 pre-adipocytes were cultured in DMEM 
containing 10% FCS, and 2 days after cells reached confluency 
differentiation was induced by changing the culture medium to DMEM 
containing 10% FCS, 10 µg/ml insulin, 1 µM dexamethasone and 0.5 mM 
isobutylmethylxanthine. 2 or 3 days later, this medium was replaced with 
DMEM supplemented with only 10 µg/ml insulin, and cells were kept for 2 
days. The medium was then replaced with DMEM containing 10% FCS 
every 2 days. Cellular morphology was observed using a Nikon Diaphot 
inverted microscope (10× objective with numerical aperture of 0.25). 
 
2-D Gel electrophoresis and MALDI-TOF. Proteins were separated on a 
4–12% Bis-Tris Mops-SDS gradient gel and stained with Silverquest silver 
stain. Three protein spots on the two-dimensional gel were excised, and in-
gel digestion was carried out with a Montage in-gel digestion kit (Millipore). 
Digests of protein bands were first analyzed by MALDI-TOF mass 
spectrometry, and samples of adequate quality were then subjected to 
microliquid chromatography/electrospray ionization/tandem MS (micro-LC-
ESI-MS/MS) using a QTOF Ultima system (Waters, Milford, MA). MS/MS 
fragmentation spectra were analyzed using the PROTEINLYNX software 
package. 
 
RNA isolation and Northern blot analysis. Total RNA (12 µg) was isolated 
using the acid-guanidinium thiocyanate-phenol-chloroform method and 
subjected to Northern blot analysis as previously described [Koziczak, 2001 
#568].  
 
Quantitative real-time PCR. Total RNA extraction for RT-PCR was 
performed using RNeasy kits (Qiagen) according to the instructions from the 
manufacturer. RT-PCR for PAI-1 was carried out as described [Venugopal, 
2004 #823]. 
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Immunoprecipitation and Western blotting. Immunoprecipitation and 
Western blotting were performed as previously stated [Venugopal, 2004 
#823]. 
 
Cell-penetrating peptide treatment. The sequence of the interfering 
peptide was derived from the pRB-binding region of E2F1 (aa 402-419: 
LDYHFGLEEGEGIRDLFD) [Helin, 1992 #620]. A control peptide with the 
same amino acid composition, GEELEGFHDGLLDFDIR, was prepared by 
randomly shuffling the sequence of this peptide. Cell-penetrating peptides 
were prepared by coupling these peptides to the carboxyl terminus of the 
cell-penetrating region of the HIV tat protein (aa 47-57: RRRQRRKKR) via 
hinge peptide G. Differentiated adipocytes were separated from 
undifferentiated cells using a Percoll density gradient as previously 
described [Venugopal, 2004 #823]. The penetrating peptide was then added 
to cells, incubated for 16 h and then subjected to various treatments. 
5.5 Results  
Key glycolytic enzymes bind to caveolin and perturbation of caveolar 
microdomains leads to modifications of these enzymes 
 
 
OH-H+
Fig. 5.7. Two-dimensional gel screening for changes in caveolin 
interactions upon cyclodextrin treatment. (A) Total cell extracts were 
prepared from cells treated with or without cyclodextrin for 50 min. Caveolin-
1 protein was immunoprecipitated using anti-caveolin-1 antibody. The 
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protein complexes were eluted with Glycine elution buffer and analysed 
using two-dimesional gel electrophoresis. Specific spots that were altered 
upon cyclodextrin treatment were excised and digested. They were then 
identified by MALDI-TOF.   
 
To screen the caveolin-1 interaction partners and to detect changes in their 
interactions upon cholesterol depletion, we treated the 3T3L1 adipocytes 
with increasing concentrations of MBCD and then subjected the total cell 
extract to two-dimensional gel electrophoresis. Three spots showed 
charecterestic shift towards the negative pH. This may indicate 
dephosphorylation, but needs to be examined. The spots that underwent 
characteristic changes upon MBCD treatment were analyzed using MALDI-
TOF. As show in the Fig. 5.7, three spots that underwent characteristic 
change were identified as fructose-biphosphate aldolase, glyceraldehyde-3 
phosphate and phosphoglycerate kinase-1, three key glycolytic enzymes.  
 
 
 
 
 
 
 
 
 
(This part is left intentionally blank) 
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Perturbation of caveolar microdomains activates two pathways that are 
critical for hyperglycemia-induced damage 
 
 
Fig. 5.8. Effect of 
cholesterol depletion 
on signal pathways 
that are critical for 
hyperglycemia-
induced damage. (A) 
Cells treated with or 
without glucose 
(30mM) for 48 h were 
treated with MBCD and 
insulin. The membrane 
fraction of the total cell 
lysate was prepared 
and run on an SDS-
PAGE gel followed by 
blotting with anti-PKC 
antibodies. (B) The 
cells were subjected to 
similar treatment and 
the SPI-1 protein was immunoprecipiated before Western blot analysis using 
anti-O-linked GlcNAc antibody. (C) Cells were treated with increasing doses 
of MBCD. PAI-1 gene expression was analyzed by Northern blot.  
 
Since the 3 key glycolytic enzymes bind to caveolae, we investigated the 
potential effects that caveolar dysfunction might have on glycoysis and its 
associated pathways. We looked at PKC activation and glucosamine-
induced SP-1 glycosylation. Both of these pathways are known to activate 
PAI-1 gene transcription. High glucose treatment has only a slight positive 
effect on PKC activation as measured by translocation of PKC to membrane 
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fractions (Fig. 5.8A). MBCD treatment by itself did not have any effect on 
PKC activation. Notably, MBCD could activate cells that were subjected to 
hyperglycemic conditions in a dose-dependent manner. Similarly, high-
glucose as well as insulin increased the glycosylation of SPI-1 transcription 
factors, but were augmented by MBCD treatment (Fig. 5.8B).  Subsequently 
MBCD treatment in hyperglycemic conditions upregulated the gene 
expression of PIA-1 in a dose-dependent manner. 
 
5.6 Discussion 
 
This study found three key glycolytic enzymes to be associated with caveolin. 
Previously, it has been shown in vascular smooth muscle cells that 
glycolysis and gluconeogenesis are compartmentalized [Hardin, 1995 
#2315]. This makes sense if we take into account that glycolysis and 
gluconeogenesis are opposing pathways (the former consumes glucose, 
while the later produces it) despite the fact that they share eight common 
enzymes. It was later shown that glycolysis occurs in caveolar microdomains 
[Vallejo, 2004 #2316].   
 
Recently, it was also shown that phosphofructokinase, a critical mediator of 
glycolysis, binds to caveolin-1 [Vallejo, 2005 #1184] and caveolin-3 [Vallejo, 
2004 #1193] and this interaction is required for the membrane recruitment of 
this enzyme. Taken together, it is plausible to assume that caveolae might 
represent the cellular location of glycolytic activity. Perturbation of caveolar 
function therefore could lead to an inhibition of glycolysis and the 
subsequent activation the four pathways that are critical mediators of 
vascular complications associated with hyperglycemia. Upon treatment with 
cyclodextrin, we observe some shifts in the spots representing glycolytic 
enzymes (Fig. 5.8). This may indicate, but does not prove, that cyclodextrin 
treatment leads to post-translational modifications of these enzymes and in 
turn may affect their activities. The precise nature of modifications in these 
enzymes remains to be investigated.  
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We show that hyperglycaemic conditions in adipocytes lead to a slight 
activation of the 2 pathways implicated in hyperglycemia-induced vascular 
complications (Fig. 5.8). Interestingly, the hyperglycemia-induced activation 
was much stronger in the presence of cyclodextrin treatment. This led us to 
propose a working model, where caveolar dysfunction strengthens the 
glucose-induced inhibition of glycolysis and activation of the pathological 
pathways. Much of the work to test the validity of this hypothesis remains to 
be conducted. This includes reconfirming the interaction of caveolin and 
glycolytic enzymes by reverse immunoprecipitation, identifying the precise 
nature of the modifications that caveolar dysfunction imposes on glycolytic 
enzymes, testing the activity of these enzymes upon caveolar disruption, 
looking at the role of superoxide anions in this phenomenon, analyzing the 
effect of caveolar dysfunction on the remaining two pathways (polyol 
pathway and AGE pathway), and finally to test if the proposed four pathways 
are hyper-activated in caveolin-1 knock-out mice. 
5.7 Working models  
 
Figure 5.9. Glycolytic enzymes bind to caveolin-1 and perform their 
reactions in caveolar microdomains.  
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Figure 5.10. Disruption of caveolar microdomains leads to the inhibition of 
membrane-associated glycolysis and subsequent shunting of glycolytic 
intermediates into four pathways that are critical for vascular abnormalities in 
obese and diabetic conditions. Activation of these pathways leads to the 
upregulation of PAI-1 gene expression. 
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6.1 Specific research objectives 
In the earlier sections, we show that caveolar dysfunction-induced signaling 
defects lead to the upregulation of PAI-1 gene expression in adipocytes. 
Many studies have shown that adipose tissue-derived PAI-1 is primarily 
responsible for the elevated plasma PAI-1 levels in obese patients. This part 
of the study was aimed at understanding the molecular mechanisms which 
enable adipocytes to be a major PAI-1 producing organ. We further explored 
the pharmacological modulation strategy to inhibit PAI-1 production in 
adipocytes without causing unwanted effects such as cell-cycle re-entry. 
6.2 Abstract 
Obesity is characterized by elevated levels of circulating plasminogen 
activator inhibitor-1 (PAI-1), which contribute towards the development of 
obesity-driven secondary disorders such as type-2 diabetes mellitus, 
cardiovascular complications and certain types of cancer. This increase in 
plasma PAI-1 levels under obese conditions is attributed to an increase in 
PAI-1 derived from adipose tissue. Previous sections in this thesis show that 
caveolar dysfunction leads to signal transduction defects associated with 
secondary disorders of obesity, and also results in the upregulation of PAI-1 
levels in cultured adipocytes. This study shows that adipose tissue evolved 
into a major PAI-1 producing organ by gaining capacity during adipocyte 
differentiation to respond to inducers of PAI-1 transcription. This is mediated 
by a decrease in E2F1 protein levels, an increase in retinoblastoma protein 
(pRB) levels and a decrease in pRB phosphorylation, all leading to a 
decrease in levels of free E2F, a known transcriptional repressor of PAI-1. 
Depletion of E2F1-3 was sufficient for inducers such as insulin to potently 
induce PAI-1 gene expression in pre-adipocytes. Conversely, forced release 
of pRB-bound endogenous E2F using cell-penetrating peptides can 
suppress PAI-1 gene expression in adipocytes without causing unwanted 
effects such as cell cycle re-entry. This study describes the novel paradigm 
of cellular differentiation-associated increase in PAI-1 gene expression 
which is mediated by a decrease in repressor activity, and describes a way 
 87
of desensitizing terminally differentiated cells to PAI-1 inducing agents by 
restoring endogenous repressor activity. 
 
6.3 Introduction  
Obesity has reached epidemic proportions globally, with more than 1 billion 
adults overweight – at least 300 million of them clinically obese – and is a 
major contributor to the global burden of chronic disease and disability. It is 
not obesity per se, but its chronic, life-threatening secondary disorders such 
as type 2 diabetes mellitus (T2DM), cardiovascular complications (1) and 
certain types of cancers (2) that burden healthcare systems worldwide. The 
precise molecular mechanisms that trigger these secondary disorders under 
obese conditions have been a subject of intense investigation, but remain 
inconclusive.   
 
A simplified approach in this direction would be to identify proteins whose 
levels or activity are altered in obesity and are known independently to 
contribute to these secondary disorders. Plasminogen activator inhibitor-1 
(PAI-1), a physiological inhibitor of plasminogen activators (uPA/tPA) and 
vitronectin, could be a viable candidate in this regard. Plasma PAI-1 levels 
are known to be elevated in obese patients (3). Congruently, a dramatic 
increase in plasma PAI-1 levels (∼5-fold) has been observed in genetically 
obese (ob/ob) mice, in comparison with their lean counterparts (4). 
Conversely, weight loss has led to a subsequent reduction in plasma PAI-1 
levels in obese patients (5, 6). 
 
Elevated levels of PAI-1 are implicated in many chronic disorders that are 
secondary to obesity. PAI-1 is known to play important roles in eliciting 
thrombosis, fibrosis and vascular remodeling, thus contributing to a wide 
variety of cardiovascular disorders. The role of PAI-1 in cardiovascular 
complications has been reviewed elsewhere (7). 
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In line with the observation by us and others that PAI-1 can induce insulin 
resistance by inhibiting the interaction between vitronectin and αvβ3 integrin 
(8, 9), it has recently been show that PAI-1 knock-out mice are resistant to 
high-fat-diet-induced insulin resistance (10, 11), indicating a role for PAI-1 in 
the pathogenesis of obesity-driven insulin resistance and hence T2DM. 
Moreover, levels of plasma PAI-1 have been shown to be a prognostic 
marker of T2DM independent of insulin resistance and other known risk 
factors for diabetes (12). 
 
The role of PAI-1 in cancer progression is rather controversial. Nevertheless, 
in almost all cancer types that are associated with obesity (2), a role for PAI-
1 has been proposed. Possible mechanisms by which PAI-1 contributes to 
cancer dissemination include the prevention of excess degradation of the 
extra-cellular matrix, modulating cell adhesion (13), promoting angiogenesis 
(14), inhibiting apoptosis (15) and stimulating cell proliferation (16). Taken 
together, elevated levels of PAI-1 in obese patients may be an important 
factor contributing to obesity-driven chronic secondary disorders. Needless 
to say, understanding the molecular mechanisms that lead to PAI-1 
upregulation in obesity assumes paramount importance. 
 
The increase in plasma PAI-1 levels that is associated with obesity could be 
attributed to adipose tissue. Adipose tissue is one of the largest endocrine 
organs in obese patients (17). Weight loss in humans, either by exercise 
(18) or by surgical removal of fat (19), leads to a decrease in plasma PAI-1 
levels, which rise again if weight is regained (20). Furthermore, comparative 
analysis of PAI-1 gene expression in various tissues of ob/ob mice and their 
wildtype counterparts shows that, in ob/ob mice, PAI-1 upregulation was 
significantly higher in the adipose tissue but only modestly increased in other 
tissues. These observations indicate that adipose tissue is a major, possibly 
the largest, contributor to plasma PAI-1 in conditions of obesity (4). 
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Adipose tissue is primarily composed of adipocytes that are formed by the 
differentiation of pre-adipocytes, a process commonly referred to as 
adipogenesis. Under serum-starved conditions, neither 3T3L1 pre-
adipocytes nor differentiated adipocytes showed any significant PAI-1 gene 
expression (see results). But in the presence of serum (see results) or 
insulin (21), adipocytes, but not pre-adipocytes, showed significant PAI-1 
gene expression. Taken together, this suggests that adipogenesis, as such, 
may not induce PAI-1; rather it enhances the potential of cells to respond to 
PAI-1 inducers (e.g. insulin) in serum. 
 
Hyperinsulinemia has been shown to be associated with obesity and insulin 
resistance. The evidence for the pathophysiological role of insulin in the 
elevation of PAI-1 comes from the following observations. Conditions that 
increase endogenous plasma insulin levels (e.g. high calorie, high 
carbohydrate meals) were associated with increases in plasma PAI-1, 
whereas conditions that reduced endogenous insulin (e.g. fasting or 
treatment with metformin or troglitazone) were associated with decreases in 
plasma PAI-1 (22, 23). Moreover, administration of exogenous insulin in 
rabbits (24), mice (4) and human subjects (25) significantly increased 
plasma PAI-1 levels.  
 
The E2F family of transcription factors are known to reversibly bind to the 
pocket proteins (pRB, p107 and p130) and are key regulators of the cell 
cycle. E2F1-3 complex with pRB, and the hyperphosphorylation of pRB 
leads to the release of E2F1-3 isoforms. Contrary to the earlier belief that 
E2F1-3 are transcriptional activators and E2F4-5 are transcriptional 
repressors (26), we have previously demonstrated that E2F1-3 act as 
transcriptional repressors of the PAI-1 gene in a cell type-independent 
manner (27, 28). Subsequently, other groups have shown repressive effects 
of E2F1 (29), E2F2 (30) and E2F3 (31) on other target genes. Using 
chromatin immunoprecipitation assays, it was shown by Wells J et al that 
E2F1-3 can directly bind to the PAI-1 promoter in a tissue specific-manner 
(32). As the compromise of E2F activity was shown to be required for 
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cellular differentiation (33), it would be intriguing to investigate if it can also 
be held responsible for the enhanced PAI-1 biosynthetic potential attained 
during adipogenesis. 
 
As adipose tissue is the major contributor of plasma PAI-1, the crux of 
obesity-associated increase in plasma PAI-1 levels lies in the enhanced PAI-
1 biosynthetic potential acquired during adipogenesis. It is this gain of 
function that enables the adipocytes to respond to various stimuli to express 
and secrete PAI-1. In this study, we investigated the mechanisms by which 
adipogenesis empowers the cells to respond to PAI-1 inducers such as 
insulin, which happens to be a major physiological stimulus in conditions of 
diabesity®. We also explored the potential of inhibiting PAI-1 gene 
expression in terminally differentiated adipocytes by the forced release of 
endogenous E2F (bound to pRB) without effectuating cell-cycle re-entry.  
6.4 Experimental Procedures  
Reagents. Insulin (I-5500) was obtained from Sigma. Monoclonal antibodies 
against E2F1 (KH-95) and E2F2 (TFE-25), and rabbit polyclonal antibodies 
against E2F3 (C-18), E2F4 (C-20), E2F5 (C-20), pRB (M-153), p130 (C-20), 
p107 (C-18), IRS-1 (C-20), Erk and PAI-1 (H-135) were from Santa Cruz 
Biotechnology. Rabbit polyclonal antibodies against phospho-pRB (Ser-795) 
and phospho-Erk were from Cell Signaling. Rabbit polyclonal antibodies 
against Shc and phospho-tyrosine (G410) were from Transduction 
Laboratories. The sheep polyclonal antibody against PAI-1 was from 
American Diagnostics. 5,6-dichloro-1-ß-D-ribofuranosylbenzimidazole (DRB) 
was from Fluka. Br-dU incorporation kit (Cat. No. 1296736) was from Roche 
Diagnostics. 
 
Adipocyte differentiation. 3T3-L1 pre-adipocytes were cultured in DMEM 
containing 10% FCS, and 2 days after cells reached confluency 
differentiation was induced by changing the culture medium to DMEM 
containing 10% FCS, 10 µg/ml insulin, 1 µM dexamethasone and 0.5 mM 
 91
isobutylmethylxanthine. 2 or 3 days later, this medium was replaced with 
DMEM supplemented with only 10 µg/ml insulin, and cells were kept for 2 
days. The medium was then replaced with DMEM containing 10% FCS 
every 2 days. Cellular morphology was observed using a Nikon Diaphot 
inverted microscope (10× objective with numerical aperture of 0.25). 
 
Oil-red O staining. Cells were washed twice with phosphate-buffered saline 
(PBS) and fixed with 3.7% formaldehyde solution for 1 h. After washing twice 
with PBS, cells were stained with oil-red O [60:40 (v/v) dilution in water of 
0.5% stock solution (v/v, in isopropanol)] for 1h. Cells were then washed 
twice with PBS and twice with water. 
 
RNA isolation and Northern blot analysis. Total RNA (12 µg) was isolated 
using acid-guanidinium thiocyanate-phenol-chloroform method and 
subjected to Northern blot analysis as previously described (28).  
 
Nuclear run-on transcription assay. Transcriptionally active nuclei from 
pre-adipocytes and adipocytes were extracted (34) and the amount of nuclei 
was equalized based on the 280 nm absorbance of the total nuclear lysate. 
A run-on assay was performed in the presence of [ -32P]UTP according to 
the basic protocol (35), with minor modifications. Purified mRNA from both 
samples was hybridized to nylon filters containing linearized and immobilized 
PAI-1 and GAPDH cDNA (1µg of each) and exposed to a phosphoimager. 
 
Quantitative real-time PCR. Total RNA extraction for RT-PCR was done 
using RNeasy kits (Qiagen) according to the instructions from the 
manufacturer. RT-PCR for PAI-1 was carried out as described (34). 
 
Immunoprecipitation and Western blotting. Immunoprecipitation and 
Western blotting were performed as previously stated (34). 
 
siRNA nucleofection. The small interfering RNA (siRNA) used for targeting 
E2F mRNA has the following sequence: E2F1: sense, 5'-GAC UCC UCG 
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CAG AUC GUC AUC-3' and antisense, 5'-UGA CGA UCU GCG AGG AGU 
CGA-3'; E2F2/3: sense, 5'-ACA UCA CCA ACG UGC UGG AAG-3' and 
antisense, 5'-UCC AGC ACG UUG GUG AUG UCG-3'; control siRNA: sense, 
5'-GUACCUGACUAGUCGFCAGAAG-3' and antisense, 5'-UCU GCG ACU 
AGU CAG GUA CGG-3'. Each siRNA (final concentration 1 µM) was mixed 
with 3T3L1 cell suspension (1×106 cells in 0.1 ml buffer-V/transfection), 
transferred to a 2-mm electroporation cuvette, and electroporated using an 
Amaxa Nucleofector™ (Amaxa, Germany) the program T-20. After 
electroporation, cells were immediately transferred to 1 ml growth medium, 
and cultured in 6-well plates at 37°C until analysis. 
 
Electromobility shift assays. Nuclear extracts (5 µg) were first incubated at 
room temperature for 15 min in 20 µl binding reaction mixture containing 50 
mM KCl, 20 mM HEPES (pH 7.9), 0.2 mM EDTA, 6% glycerol, 0.5% Ficoll 
400, 1 µg salmon sperm DNA, 6 µg bovine serum albumin and 1 mM DTT 
with or without penetrating peptide and antibodies, followed by a further 15-
min incubation after addition of 0.3 ng radio-labeled oligonucleotide probes. 
Oligonucleotide probes were radio-labeled using E. coli polynucleotide 
kinase and [γ-32P]ATP. Aliquots (5 µl) of reaction mixture were separated in 
a 4.5% polyacrylamide gel run in 0.25×TBE buffer at room temperature. The 
gel was dried and analyzed on a PhosphorImager. 
 
Cell-penetrating peptide treatment. The sequence of the interfering 
peptide was derived from the pRB-binding region of E2F1 (aa 402-419: 
LDYHFGLEEGEGIRDLFD) (36). A control peptide with the same amino acid 
composition, GEELEGFHDGLLDFDIR, was prepared by randomly shuffling 
the sequence of this peptide. Cell-penetrating peptides were prepared by 
coupling these peptides to the carboxyl terminal of the cell-penetrating 
region of the HIV tat protein (aa 47-57: RRRQRRKKR) via hinge peptide G. 
Differentiated adipocytes were separated from undifferentiated cells using a 
Percoll density gradient as previously described (34). The penetrating 
peptide was then added to cells, incubated for 16 h and then subjected to 
various treatments. 
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BrdU incorporation assay. Adipocytes were enriched using a Percol 
density gradient as described above. About 1×105 adipocytes were then 
seeded in a 6-well plate containing cover slips, incubated overnight in growth 
media. The media was then replaced with fresh media supplemented with 
bromodeoxyuridine (BrdU). The cells were subjected to various treatments 
for 48 h, washed with PBS-, fixed with ethanol fixative (25 mM glycine in 
100% ethanol; pH 2) at −20°C for at least 20 min and then subjected to 
immunofluorescence analysis according to the instruction from the 
manufacturers (BrdU Detection Kit-1, Roche). Cellular morphology was 
observed using a Nikon Diaphot inverted microscope (10× objective with 
numerical aperture of 0.25). Fluorescence was visualized with a Zeiss 
Axioplan fluroscence microscope (63× oil objective with numerical aperture 
of 1.4).  
6.5 Results  
PAI-1 levels are upregulated during adipogenesis  
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Fig. 6.1. PAI-1 gene expression during adipogenesis. 3T3L1 cells were 
differentiated and subjected to (A) microscopic examination and (B) oil-red O 
staining. (C) The total RNA was collected from cells on every day of 
adipogenesis, and mRNA levels of PAI-1, PPARγ and GAPDH (control) were 
measured using Northern blot analysis. 
 
The differentiation of 3T3L1 pre-adipocytes into adipocytes was verified by 
microscopic observation of cell morphology changes (Figure 6.1A) and lipid 
staining using Oil-Red O (Figure 6.1B). 8 days after the induction of 
differentiation, almost all cells contained vacuoles, a lipid storage 
compartment, and were positive for lipid staining. The differentiation process 
(adipogenesis) was accompanied by an increase in PAI-1 gene expression, 
which was comparable to the increase in the gene expression of PPARγ, a 
well-known adipocyte differentiation marker (Figure 6.1C). 
 
Increase in PAI-1 mRNA levels is transcriptional 
 
 
 
 
 
 
 
 
 
 
Fig. 6.2. PAI-1 mRNA stability during adipogenesis. (A) Transcriptionally 
active nuclei from both pre-adipocytes and adipocytes were subjected to 
run-on assays. Purified mRNA from both samples was hybridized to nylon 
membranes containing linearized and immobilized cDNA from PAI-1 and 
GAPDH and then exposed to a phosphoimager. (B) Both pre-adipocytes 
(filled circles) and adipocytes (open circles) were treated with DRB (20 
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µg/ml) and cells were collected at various time points. PAI-1 levels 
normalized to GAPDH levels were plotted on a semi-log scale and linear 
regression lines drawn using SigmaPlot. 
 
The increase in mRNA levels could be due to an increase in either mRNA 
synthesis, mRNA stability, or both. To investigate this, we looked at the state 
of PAI-1 gene transcription in both pre-adipocytes and adipocytes by nuclear 
run-on assays. PAI-1 transcription appears to be limited in pre-adipocytes, 
while substantial in adipocytes (Figure 6.2A). Furthermore, we examined the 
half-lives of PAI-1 mRNA in pre-adipocytes and adipocytes using DRB chase 
experiments. As shown in Figure 6.2B, the half-lives of PAI-1 mRNA in pre-
adipocytes and adipocytes were 4.2 and 1.8 h, respectively. This result 
indicates that PAI-1 mRNA becomes rather unstable during adipogenesis. 
Therefore, the elevation of PAI-1 mRNA levels in adipocytes is due to 
transcriptional activation of the PAI-1 gene and does not involve an increase 
in mRNA stability. 
 
Increase in PAI-1 gene expression is a result of enhanced biosynthetic 
Fig. 6.3. The ro
potential acquired during adipogenesis 
le of serum and 
independent experiments were quantified and normalized with GAPDH. 
insulin in effecting PAI-1 gene 
expression during 
adipogenesis. (A) Cells at 
various stages of adipocyte 
differentiation were subjected to 
overnight serum-starvation and 
then induced with 10 µg/ml 
insulin (1.7 µM) for 2 h. Total 
RNA was prepared and analyzed 
for PAI-1 and GAPDH levels by 
Northern blot analysis. (B) PAI-1 
gene expression from three 
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Cellular gene expression can be influenced by both extrinsic (e.g. 
extracellular growth factors) and intrinsic factors (e.g. transcription factors). 
To understand the relative role of these factors in the increase of PAI-1 gene 
expression associated with adipogenesis, the cells were deprived of 
extracellular inducers by culturing them overnight in the absence of serum. 
Interestingly, serum-starved cells, irrespective of their state of differentiation, 
expressed very low levels of PAI-1 mRNA, which did not change during 
adipogenesis (Figure 6.3). On the other hand, when supplemented with 
insulin, these cells could induce PAI-1 gene expression in a manner 
positively correlating with the extent of differentiation. Even high 
concentrations of insulin (1.7 µM) could barely induce PAI-1 gene 
expression in pre-adipocytes, whereas in terminally differentiated adipocytes 
more than 7-fold induction was observed. These results strongly suggest 
that adipogenesis as such may not induce PAI-1; rather, it enhances the 
potential of cells to respond to PAI-1 inducers (e.g. insulin) in serum. 
Inducibility of the PAI-1 gene is associated with a decrease in free E2F 
levels 
 
 
Fig. 6.4. E2F DNA-binding activity during adipogenesis. (A) E2F DNA-
binding activity of nuclear extracts from various days of adipogenesis was 
assessed by EMSA. (B) In the gel-shift assays, nuclear extracts prepared 
from adipocytes (day 8) were incubated with the same radioactive 
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oligonucleotide used in (A) together with an increasing amount of a cold 
oligonucleotide DHFR containing an E2F-binding site or mutant DHFRm. (C) 
Nuclear extracts from adipocytes (day 8) were preincubated with different 
antibodies for 15 min and then analyzed for E2F DNA-binding activity by 
EMSA. 
 
We have previously shown that free E2F1-3 that is not bound to pocket-
roteins can act as a transcriptional repressor of PAI-1 gene expression. p
Removal of repressor activity is a plausible mechanism through which 
inducers can gain biosynthetic potential. To find out if an inverse correlation 
between E2F activity and PAI-1 gene expression during adipogenesis exists, 
we employed gel-shift assays to assess the state of E2F activity (free E2F) 
using an E2pro oligonucleotide probe that contains E2F recognition sites 
derived from the adenovirus E2 promoter (37). Both free and complex forms 
of E2F1-6 are able to bind to this E2F recognition element, and can be 
distinguished from each other by differential migration in DNA gel-shift 
assays. The pattern of protein-DNA complexes showed differentiation-
associated changes in gel-shift assays (Figure 6.4A). In proliferating pre-
adipocytes (day −3), several sizes of DNA-protein complexes were detected 
and, upon reaching confluency (day 0), the intensity of a higher band (B) and 
lower bands (C) declined and a new band (D) appeared. During 
differentiation (day 0-8), a further decrease in the intensity of the lower 
bands (C) was observed. The specificities of these DNA-protein complexes 
were examined by competition experiments using a competitor 
oligonucleotide with an E2F recognition sequence derived from the 
dihydrofolate reductase (DHFR) promoter (38). Except for band A, all 
complexes found in extracts of pre-adipocytes and adipocytes were out-
competed by the DHFR promoter-derived specific oligonucleotide, but not by 
a mutated oligonucleotide, in a dose-dependent manner (Figure 6.4B), 
suggesting that these bands represents E2F isoforms that are either free or 
in complexes with other protein(s). Super-shift assays of adipocyte (day 8) 
nuclear extracts using specific antibodies revealed that complex D contained 
E2F bound to p130 and complex E contained E2F bound to pRB (Figure 
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6.4C). The fast-migrating DNA-protein complexes (C) are present only in 
proliferating pre-adipocytes, but are progressively reduced during 
differentiation. These bands, super-shifted with antibodies against E2F (data 
not shown), may reflect free, active E2F. Other complexes may represent 
higher molecular weight forms comprising E2F and other proteins such as 
p107, HDAC, cdk2, cyclin A and DP (39, 40). Taken together, a significant 
reduction in free E2F levels is found to be associated with adipogenesis.  
 
The decrease in free E2F levels may be due to changes in protein 
vels of E2F1 and pRB, and the phosphorylation status of pRB le
 
 
Fig. 6.5. Analysis of the mechanisms that contribute to a decrease in 
ee E2F levels during adipogenesis. (A) E2F1 and (B) E2F2/3 protein 
 
fr
levels were measured at various stages of adipogenesis. (C) Both pre-
adipocytes and adipocytes were treated with or without insulin (100 nM) for 
10 min and analysed for pRB phosphorylation. (D) 500 µg total cell lysates of 
pre-adipocytes and adipocytes (day 8) were first immunoprecipitated and 
then immunoblotted with anti-pRB antibody. 
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In principle, the decrease in free E2F levels could be due to a decrease in 
2F protein levels, an increase in pRB protein levels or a decrease in pRB 
hosphorylation. To understand how E2F activity is reduced during 
 
on PAI-1 gene expression 
 pre-adipocytes and 
16 h, followed by treatment with or without insu
RNA was extracted from the cells and then analy
E
p
adipogenesis, the protein levels of E2F1-3 and pRB, as well as the 
phosphorylation levels of pRB, were assessed. E2F1 levels were 
progressively reduced during adipogenesis, while E2F2 and E2F3 levels 
remained unchanged (Figure 6.5A,B). It appears that adipogenesis results in 
increasing pRB phosphorylation status (Figure 6.5C) and decreasing pRB 
protein levels (Figure 6.5D).  
 
Increase in PAI-1 gene expression is a result of a decrease in E2F 
activity 
Fig. 6.6. Effect of E2F1-3 
in
adipocytes. (A) 3T3L1 pre-
adipocytes were 
electroporated with siRNA 
against respective E2F 
isoforms. After 48 h, the 
cells were collected and 
analyzed for E2F1-3 
isoforms using Western 
blot analysis. (B) Cells 
were electroporated with 
siRNA against respective 
E2F isoforms. After 32 h, 
the cells were subjected to 
serum starvation for about 
lin (1 µM) for 2 h. The total 
zed for PAI-1 mRNA levels 
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using RT-PCR with 18S rRNA as an internal control. (C) Fully differentiated 
adipocytes were treated with specific or control peptide for 16 h followed by 
treatment with insulin for 2 h. PAI-1 and GAPDH mRNA levels were 
analyzed by Northern blot. 
 
 
Further to our demonstration of an inverse correlation between E2F activity 
nd PAI-1 levels (Figure 6.4), we sought to verify whether this correlation is 
on-consequential or if the decrease in E2F activity is indeed responsible for 
as found to 
ignificantly reduce insulin-induced PAI-1 mRNA levels in differentiated 
ession without causing cell-cycle re-entry 
a
n
the increase in PAI-1 levels during adipogenesis. To address this question, 
we performed RNAi-mediated gene silencing of E2F1-3 in pre-adipocytes by 
electroporating siRNAs that target E2F mRNA. Downregulation of E2F 
isoforms was found to be most effective 48 h after electroporation using 
protocol T-20 (data not shown). As shown in Figure 6.6A, transfection of 
cells with specific siRNAs directed against E2F1 and E2F2/3 mRNAs 
downregulated the respective proteins. Under serum-starved conditions, 
neither siE2F1, siE2F2/3 nor insulin treatment by themselves had any 
significant effect on PAI-1 levels, but insulin strongly induced PAI-1 mRNA in 
cells pre-treated with siE2F (Figure 6.6B). The magnitude of PAI-1 induction 
was highest upon depletion of E2F1-3 or E2F1 alone followed by E2F2/3. 
These results indicate that downregulation of E2F1-3 enhances the potential 
of insulin to induce PAI-1 gene expression in pre-adipocytes.  
 
Conversely, the cell-penetrating peptide that physically disrupts the E2F-
pRB binding, and thereby releases E2F isoforms (34), w
s
adipocytes (Figure 6.6C). This indicates that an increase in free E2F1-3 
levels diminishes the potential of insulin to induce PAI-1 gene expression in 
adipocytes. 
 
Reactivation of E2F by cell-penetrating interfering peptide reduces PAI-
1 gene expr
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Fig. 6.7. Effect of cell-penetrating interfering peptide on BrdU
incorporation. Differentiated adipocytes were treated either with specific
 
 
eptide (18 h), control peptide (18 h) or dl520 (48 h). (A) The cells were 
g peptide is supportive of the novel pharmacological 
aradigm of disrupting E2F-pRB interaction to suppress PAI-1 levels. The 
6.6 Discussion  
p
analyzed using microscopic examination and subjected to (B) BrdU 
incorporation assay. 
 
The dramatic reduction of insulin-induced PAI-1 levels by the cell-
penetrating interferin
p
main concern in this strategy is that the forced release of free E2F may 
induce cell-cycle re-entry and uncontrolled cell growth in terminally 
differentiated cells. We therefore examined the effect of these peptides on 
DNA synthesis in adipocytes. Terminally differentiated adipocytes were 
treated with specific (40 µM) and control peptide (40 µM) for 48 h, analyzed 
by light microscopy and then subjected to BrdU incorporation assay. A 
mutant of human adenovirus type 5 (dl520) that is known to induce cell-cycle 
re-entry in adipocytes was used as a positive control (41). Untreated cells 
and cells treated with specific peptide or control peptide showed similar 
morphology and absence of BrdU incorporation (Figure 6.7), while the dl520-
treated cells showed altered morphology and BrdU incorporation. This 
suggests that interfering peptide treatment does not lead to cell-cycle re-
entry in terminally differentiated adipocytes.  
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Adipose tissue, a major source of plasma PAI-1, is thought to be the largest 
endocrine organ in obese patients (42), thus offering a plausible explanation 
as to why elevated plasma PAI-1 levels are a biochemical hallmark of 
y was aimed at understanding the molecular mechanisms 
n the decrease in free E2F levels (Figure 6.4A) and the 
crease in PAI-1 gene expression (Figure 6.1C) during adipogenesis. The 
ression during adipogenesis could be a direct result of enhanced 
sulin signaling (e.g. via the mitogen-activated protein kinase pathway) (44) 
obesity. This stud
which enable adipocytes to be a major PAI-1 producing organ and to 
pharmacologically modulate those mechanisms to inhibit PAI-1 production in 
adipocytes. In agreement with other studies (21), we have shown that PAI-1 
gene expression is significantly upregulated during adipogenesis (Figure 
6.1C). The results of nuclear run-on assay suggest that this increase is 
transcriptional, while DRB chase experiments rule out a role for mRNA 
stability (Figure 6.2). Interestingly, 3T3L1 cells, irrespective of their state of 
differentiation, failed to induce PAI-1 under serum-starved conditions (Figure 
6.3). However, in the presence of serum (Figure 6.1C) or insulin (Figure 6.3), 
adipocytes, but not pre-adipocytes, showed significant PAI-1 gene 
expression, corresponding to the state of differentiation. Taken together, 
these results indicate that adipogenesis as such does not induce PAI-1; 
rather, it enhances the potential of cells to respond to PAI-1 inducers (e.g. 
insulin) in serum.  
 
Previous studies from our laboratory have shown that free E2F1-3 act as 
transcriptional repressors of PAI-1 (27). This study clearly shows an 
association betwee
in
decrease in free E2F levels is mediated through at least three mechanisms: 
a decrease in E2F1 protein levels; an increase in pRB levels; and a 
decrease in pRB phosphorylation (Figure 6.5). In this analysis we did not 
consider the other pocket-proteins, p107 and p130, as they do not bind to 
E2F1-3. 
 
Adipogenesis is accompanied by a substantial increase in insulin receptor 
expression (43). One could argue that the increase in insulin-induced PAI-1 
gene exp
in
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and the inverse correlation between free E2F1-3 levels and PAI-1 gene 
expression is non-consequential. In pre-adipocytes under serum-starved 
conditions, neither siE2F1, siE2F2/3, nor insulin treatment by themselves 
had any significant effect on PAI-1 mRNA levels (Figure 6.6B). However, 
insulin treatment could strongly induce PAI-1 gene expression in cells 
treated with siE2F1-3. This tells us three things. Firstly, removal of repressor 
activity alone is not sufficient to induce PAI-1. This requires inducers and 
that might explain why high plasma PAI-1 levels are often associated with 
high levels of inducers such as insulin and tumor necrosis factor-α (TNF-α). 
Secondly, in the absence of E2F1-3, insulin signaling is robust enough to 
induce PAI-1 in pre-adipocytes. In other words, these results challenge the 
notion that increases in insulin-induced PAI-1 gene expression during 
adipogenesis is merely a result of an increase in expression of the insulin 
receptor. Thirdly, the results also suggest that E2F1 is a stronger repressor 
than E2F2/3 in pre-adipocytes. Conversely, release of free E2F using an 
interfering peptide was sufficient to significantly reduce insulin-induced PAI-1 
gene expression in adipocytes (Figure 6.6C). These results provide strong 
evidence that, irrespective of the state of differentiation, PAI-1 gene 
expression during adipogenesis is dependent on free E2F levels. This 
doubtless confirms that a reduction in free E2F levels, hence the relieving of 
transcriptional repression, is partly, if not wholly, responsible for the increase 
in PAI-1 gene expression during adipogenesis. Our findings are further 
supported by data from E2F1-/- mice that show a 5.7-fold increase in hepatic 
PAI-1 mRNA levels when compared to their wildtype counterparts (32). 
 
Recently, an orally active small molecule antagonist of PAI-1 (PAI-039) was 
shown to inhibit plasma PAI-1 activity and accelerate fibrinolysis of coronary 
artery thrombosis in dogs (45) and provide protection against angiotensin II-
duced aortic remodeling in mice (46). These studies offer the much-in
awaited proof-of-concept for PAI-1 inhibitors in treating cardiovascular 
complications, thereby endorsing the concept of PAI-1 inhibitors to treat 
secondary complications of obesity. Since the reactivation of E2F using cell-
penetrating interfering peptide could be successfully employed to reduce 
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PAI-1 levels in terminally differentiated adipocytes (Figure 6.6), small 
molecule antagonists of E2F-pRB interaction may offer therapeutic value. 
E2F isoforms that bind to pRB (E2F1-3) are transcriptional factors that drive 
cell proliferation and apoptosis. Therefore, the pharmacological strategy of 
disrupting E2F-pRB interaction raises a major concern because it may lead 
to unwanted effects such as cell-cycle re-entry in terminally differentiated 
adipocytes. For example, adenoviruses harboring E1A could force terminally 
differentiated Adipo5-2 adipocytes and C2C12 myoblasts to re-enter the cell 
cycle (41). Although E1A is known to act on multiple targets, including E2F, 
p300, pRB, p107, p130, TBP and AP-1, E2F activity was required for E1A-
mediated cell-cycle re-entry (47). On the other hand, it has been shown that 
E2F activation alone, either by overexpressing E2F (47) or by 
downregulating pRB (48), does not cause cell-cycle re-entry in terminally 
differentiated skeletal muscles. In line with these observations, we show that 
the cell-penetrating peptide that releases free E2F and thereby suppresses 
PAI-1 gene expression does not cause cell cycle re-entry (Figure 7).  
 
Although our data linking the decrease in E2F activity to an increase in PAI-1 
gene expression are limited to adipocyte differentiation, the results could 
have wider implications. It has been shown that E2F1-3 regulate many 
enes that are involved in cell proliferation and differentiation (33). 
to direct stimulation of adipocytes by growth factors, cytokines and 
g
Furthermore, reduction in the activity or levels of E2F isoforms (mainly 
E2F1) is critical for cell cycle arrest and subsequent differentiation of many 
cell types, including cardiomyocytes (49), C2C12 myoblasts (50), 
hepatocytes (51), platelets (52), keratinocytes (53), quail neuronal retina (54), 
P19 neurocytes (50) and embryonic granulocytes (55). This might explain 
why the major sources of plasma PAI-1 happen to be differentiated cell 
types such as adipocytes, skeletal muscles, hepatocytes, vascular 
endothelial cells and platelets, and therefore warrant further investigation 
into the role of E2F in mediating PAI-1 gene expression in these cell types. 
 
Elevated levels of PAI-1 in obesity are considered to be at least in part due 
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hormones (e.g. insulin, TNF-α and TGF-β) that are by themselves elevated 
under conditions of obesity (17). This may be achieved by the enhanced 
ensitivity acquired by adipocytes to respond to PAI-1 inducing agents. By s
using peptides that release endogenous E2F (bound to pRB), and thereby 
restoring the E2F-mediated transcriptional repression, we could desensitize 
the adipocytes to PAI-1-inducing agents without causing unwanted effects 
such as cell-cycle re-entry.  
6.7 Working model 
 
 
Figure 6.8:  Inducers such as serum, insulin (show in part-3) and caveolar 
dysfunction (show in part-1) can upregulate PAI-1 gene expression in 
adipocytes but not so much in pre-adipocytes. Reduction of free E2F-
mediated transcriptional repression during adipocyte differentiation is 
rimarily responsible for the increase in PAI-1 biosynthetic capacity of 
me) for 
roviding dl520 adenoviral vectors, Robert Medcalf (Monash University, 
elbourne) for the nuclear run-on assay protocol, Derek Brazil (Conway 
p
adipocytes, allowing inducers to elicit an increased response. Antagonists of 
E2F-pRB interaction that can release free E2F in adipocytes can suppress 
PAI-1 production in adipocytes and may thus offer therapeutic value. 
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adipocytes. We also present some evidence that caveolar dysfunction 
ays probably by the inhibition of 
nd developed progressive adipose tissue atrophy (1). 
Metabolically, the abnormalities in Cav-1 (–/–) mice are characterized by 
 no changes in plasma insulin or glucose levels (1). However, 
affected in this mice, although dramatic downregulation of insulin receptor 
activates PKC and glucosamine pathw
membrane-associated glycolysis in adipocytes. Insulin resistance is the 
central feature of T2DM, while inhibition of glycolysis and activation of PKC 
and glucosamine pathways are the characteristic signaling defects 
considered to be associated with diabesity®-induced cardiovascular 
disorders. Using caveolin-1 deficient mice as a prototype for caveolar 
dysfunction, we will discuss (see next page) if caveolar dysfunction per se 
can lead to diabetes and vascular defects in vivo. Notably, all these signaling 
defects mentioned earlier can independently lead to (but also activate 
several other pathways) the upregulation of PAI-1 that by its own can induce 
obesity-driven secondary disorders. Hence, PAI-1 may represent a nodal 
and downstream drug target. Our studies show that pharmacological 
antagonism of E2F-pRB interaction can be employed to suppress PAI-1 
gene expression. 
7.1 In vivo evidence for the causative role of caveolar dysfunction in 
diabetes 
Cav-1 null mouse develop an interesting metabolic phenotype. Preliminary 
analysis of this phenotype showed that Cav-1 null mice are resistant to diet-
induced obesity a
elevated free fatty acid and triglyceride levels, decreased leptin and Acrp30 
levels, and
when these mice were later placed on a high-fat diet for 9 mo, they were 
found to develop postprandial hyperinsulinemia (2). Additionally, when 
young Cav-1 null mice were challenged with an insulin tolerance test (ITT), 
they showed markedly decreased glucose uptake compared with wild-type 
control animals. These metabolic derangements are similar to those seen in 
prediabetic individuals in the human population, suggesting that caveolin-1 
does indeed play a critical role in insulin signaling in vivo. It was also shown 
that the metabolic signaling downstream of insulin receptor was adversely 
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was found to be the cause. It has to be noted that this does not correspond 
to the patient or animal models of diabetes. However the insulin signaling 
defects in our studies correspond well with the clinical and animal data. The 
discrepancy between the insulin signaling defects observed in the caveolin 
null mice and caveolar perturbation (in vitro) could be due to the duration 
(acute/chronic) and dosage (reduction/absence). 
In light of current data, caveolin-1 can be thought of as a major player in 
insulin signaling in tissues where it is expressed; however, loss of caveolin-1 
is not sufficient to produce fulminant diabetes. This is consistent with other 
mouse models, specifically the adipose tissue selective insulin receptor 
knockout mouse (FIRKO) (3). These mice phenotypically have relatively mild 
full-body insulin resistance despite a significant reduction in the insulin-
responsiveness of isolated adipocytes. Also of note are findings that a 
eolae in several aspects of 
 of cardiac hypertrophy. The cardiovascular 
defects observed in these mice are summarized in the following table: 
Cav-
subset of patients with severe insulin resistance were found to have 
mutations in the caveolin-binding motif of the insulin receptor (4). Taken 
together, these findings further support the idea that caveolin-1 may be 
critical for insulin signaling in the human population and that perhaps some 
diabetic patients exist with caveolin-1 mutations. 
7.2 In vivo evidence for the causative role of caveolar dysfunction in 
cardiovascular complications 
Cardiovascular complications represent one of the most striking phenotypes 
of caveolin knock out mice. Analysis of the phenotype of mice with genetic 
deletions or overexpression of specific caveolin isoforms has provided key 
evidence for the importance of caveolins and cav
the cardiovascular biology, including vascular contractility, lipid metabolism, 
angiogenesis, or the control
 
Genes Expression 
Cardiovascular Phenotypes/Abnormalities in 
Knockout (KO) Mice 
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Cav-1 Endothelia, 
smooth muscle 
cells, 
Cav-1 KO: lung hypercellularity; pulmo
hypertension/fibrosis; increased microvas
permeability; decreased angiogenesis
macrophages, 
and cardiac 
nary 
cular 
 capacity; 
athero-protection; increased neointimal hyperplasia 
vascular tone; hypertrophic fibroblasts 
(smooth muscle cell proliferation); arterial hyper-
relaxation/decreased 
cardiomyopathy due to the hyperproliferation of 
cardiac fibroblasts; reductions in life span; 
hyperactivation of eNOS and Ras-p42/44 MAP 
kinase signaling cascades in endothelial cells and 
cardiac fibroblasts, respectively. 
Cav-2 v-1 Same as Ca Cav-2 KO: lung hypercellularity; pulmonary 
hypertension/fibrosis without hypertrophic 
cardiomyopathy. 
Cav-3 Smooth muscle 
cells and cardiac 
myocytes myocytes. Also, a 
). 
Cav-3 KO: hypertrophic cardiomyopathy and 
hyperactivation of the Ras-p42/44 MAP kinase 
signaling cascade in cardiac 
human Cav-3 (T63S) mutation has been discovered 
in patients with familial hypertrophic cardiomyopathy 
(FHCM) (inherited
Cav-
1+3 
  Cav-1/3 dKO: severe hypertrophic cardiomyopathy in 
double-KO mice due to loss of caveolins in both 
cardiac fibroblasts (Cav-1) and cardiac myocytes 
(Cav-3). 
 
Table. 7.1: Summary of the ype of the caveolin knock 
out mice  
 
In an attempt to find the unde
studies have identified certain signal transduction defects that are know to 
sult in cardiovascular complications. It has been shown that the caveolar 
of eNOS signaling (5). Based on this and other evidence, it has 
cardiovascular pheot
rlying pathological mechanism, some of these 
re
platform is required for muscarinic and β-adrenergic receptor mediated 
activation 
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recently been proposed that the cardiovascular defects in caveolin deficient 
 diabetes and cardiovascular 
omplications. However there is increasing evidence linking caveolar 
dysfunction to cancer, whose association with obesity is currently being 
 acts as a tumor 
suppressor protein, inhibiting the signaling of several proto-oncogenes and 
mice may partly be due to defective eNOS signaling.  Our study proposes a 
strong link between caveolar dysfunction and inhibition of glycolysis and 
subsequent activation of four pathways that are implicated in the 
hyperglycemia-induced vascular damage. This is in agreement with other 
studies, which propose that glycolysis may be localized to the caveolar 
microdomain. Our study is the first report that links caveolar dysfunction to 
the unifying theory of diabetes-induced cardiovascular complications 
(Brownlee’s hypothesis) (6) and may further explain why caveolin null mice 
develop severe cardiovascular abnormalities.  
 
7.3 Can caveolar dysfunction lead to cancer as well? 
Our studies primarily address the potential link between caveolar dysfunction 
and two major complications of obesity, namely
c
proposed (7).  It has been suggested that caveolin-1
consequently disrupting the process of cellular transformation (8) (9) (10, 11). 
Numerous follow-up studies designed to test this hypothesis have 
contributed a myriad of evidence suggesting that caveolin-1 may indeed 
possess tumor suppressor capabilities. For instance, caveolin-1 mRNA and 
protein expression are downregulated in NIH-3T3 cells transformed with 
several activated oncogenes, such as v-Abl, Bcr-Abl, and H-Ras (G12V) (8, 
12). The ability of these transformed cells to grow in soft agar, a hallmark of 
cellular transformation, was found to inversely correlate with caveolin-1 
protein levels. The reintroduction of caveolin-1 under the control of an 
inducible promoter was sufficient to inhibit the anchorage-independent 
growth of these cells, thus reverting them to their transformed phenotype (8). 
It has been shown that targeted downregulation of caveolin-1 using a vector-
based anti-sense approach resulted in the transformation of NIH-3T3 cells, 
enhanced their anchorage independent growth, and hyperactivated the Ras-
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p42/44 mitogen-activated protein (MAP) kinase cascade (10). When injected 
into nude mice, these NIH-3T3 cells expressing the caveolin-1 anti-sense 
construct were capable of forming large tumors, compared with matched 
NIH-3T3 cells lacking the caveolin-1 anti-sense vector.  
Genetic evidence supporting the role of caveolin-1 as a tumor suppressor 
has emerged from gene mapping studies, which revealed that the human 
CAV-1 gene maps to the long arm of human chromosome 7 (7q31.1). This 
region, the D7S522 locus, encompasses a known fragile site (FRA7G) and 
is often associated with loss of heterozygosity (LOH) in various cancers, 
including breast, prostate, ovarian, and renal carcinomas (13, 14). While no 
nd the development of cancer in vivo is a multistep process 
that involves the selective and progressive loss of several tumor 
genes have been directly mapped to the D7S522 locus, the closest genes to 
this region encode caveolin-2 and caveolin-1 (15) (16). Furthermore, the 
CAV-1 promoter has been reported to be hypermethylated in several cancer 
cell lines (16).  
Thus the loss of caveolin-1 alone appears insufficient to induce cell 
transformation in vivo, but loss of caveolin-1 potentiates this process when 
combined with a transforming agent (a carcinogen or tumor-prone genetic 
background) (17, 18). This is not surprising, as the process of cell 
transformation a
suppressors (such as p53, INK4a, and Rb), as well as the mutational 
activation or upregulation of certain key protooncogenes [Ras(G12V), c-Myc, 
and c-Neu/ErbB2]. Indeed, the etiology of most cancers does not reflect 
alterations in a single gene, but rather the functional loss or induction of a 
series of key regulatory proteins that, in combination, disrupt the normal 
regulation of the cell cycle and subsequently lead to uncontrolled cell growth. 
 
7.4 PAI-1: is it a viable drug target? 
We have now discussed the effects of caveolar dysfunction in-vitro and in-
vivo. Based on these observations it is perfectly plausible to assume that 
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caveolar dysfunction can lead to insulin resistance, activation of PKC and 
glucosamine pathways. We also show that these signaling defects 
AI-1 gene expression, an important 
 
ally-active drugs 
as however remained a significant challenge. The rational design of 
rational approach since PAI-1 levels are elevated in type 2 diabetes and 
independently converge to activate P
mediator of obesity-driven disorders (19). These observations taken together,
PAI-1 may represent a nodal and downstream drug target.  
 
There has been considerable interest in the pharmaceutical industry to 
develop inhibitors of PAI-1. Inhibitory monoclonal antibodies to PAI-1 have 
been used in preclinical models of acute thrombosis and shown to enhance 
endogenous fibrinolysis (20). The modulation of PAI-1 by or
h
inhibitors has proved a challenge due to the lack of a pharmacophore. 
Wyeth undertook the HTS path, screening 35000 compounds for PAI-1 
inhibitory activity. From the 300 hits that were investigated in follow up 
studies the small molecule inhibitor; tiplaxtinin (PAI-039) was selected for 
development. This inhibitor has been reported to produce pro-fibrinolytic 
activity in a rodent model of acute arterial thrombosis (21). Recently, in the 
canine model of coronary thrombosis, pre-treatment with PAI-039 produced 
beneficial effects (22). In this paper the authors report that under control 
conditions, electrolytic injury to the coronary artery caused progressive 
occlusion and blood flow was eventually permanently interrupted. 
Pretreatment with PAI-039 prolonged the onset of coronary occlusion and 
even when permanent occlusion was observed spontaneous coronary 
reperfusion occurred in 60% of the dogs studied. This was accompanied by 
a decrease in thrombus weight. However, there was no observable effect on 
platelet aggregation or bleeding time.  
This study offers the pre-clinical proof-of-concept for the efficacy of a small 
molecule inhibitor of PAI-1 in a model of thrombosis. Therapeutic activity is 
related to the removal of ongoing inhibition of endogenous t-PA. Thus PAI-
039 could be developed as a monotherapy with a wide therapeutic window. 
Inhibiting PAI-1 rather than administering exogenous t-PA represents a 
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atherosclerosis, both risk factors for myocardial infarction, peripheral arterial 
disease and stroke. Hence increased PAI-1 activity could conceivably shift 
the homeostatic balance in favor of thrombosis in these disease states. A 
combinatorial approach based on the administration of PAI-039 along side t-
PA also offer significant opportunities since elevated PAI-1 has been 
suggested to contribute to the therapeutic failure of t-PA in the treatment of 
peripheral arterial thrombolysis. Incorporating PAI-039 into the treatment of 
these patients could therefore improve the therapeutic activity of t-PA in 
these patients. More broadly the use of PAI-039 could be employed as a 
general strategy to reduce the dosage of t-PA administered to patients in a 
variety of acute cardiovascular settings. Reducing the dosage in this fashion 
is anticipated to widen the therapeutic window for t-PA by improving the 
thrombolytic activity of t-PA while at the same time reducing the risk of 
intracerebral hemorrhage and bleeding.  
Early research on PAI-1 was primarily focused on its role in cardiovascular 
system and it was only recently that its potential role in T2DM was 
discovered (23-25) (26). Very recently, it was shown that PAI-039 can 
increase insulin sensitivity in wild-type mice (27). 
 
Wyeth is now developing an orally administered PAI-1 inhibitor (PAI-749) for 
tors. 
physiological (insulin) 
nd pathological (caveolar dysfunction) inducers of PAI-1 gene expression 
without causing unwanted effects such as cell cycle re-entry. This may 
the treatment of peripheral vascular disease and other thrombolytic 
disorders. The compound had entered Phase I clinical studies in the US by 
June 2004. Other pharmaceutical firms such as Xenova also have pre-
clinical research programs to develop PAI-1 inhibi
 
Our studies show that certain tissues such as adipose tissue are responsive 
to PAI-1 inducing signals because of the loss of free E2F-mediated 
transcriptional repression of the PAI-1 promoter during cellular differentiation. 
By disrupting the E2F-pRB interaction and thereby releasing free E2F we 
could desensitize the differentiated adipocytes to both 
a
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highlight a new drug target that is highly amenable to pharmacological 
modulation, especially since the crystal structure of E2F-1 bound to pRB has 
recently been solved, and high throughput screening for small molecular 
antagonists of E2F-pRB interaction is currently being carried out. 
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8. Conclusion 
 
 
 
 
In effect, we show that caveolar microdomains are a key signal transduction 
platform, whose perturbation can lead to a plethora of signaling defects that 
are known to elicit secondary-disorders of obesity. Elevated levels of PAI-1 
represent a ‘nodal’ and ‘downstream’ mediator of these signaling defects. By 
using peptide antagonists of E2F-pRB interaction, we could inhibit PAI-1 
gene expression in adipocytes without causing unwanted effects such as 
cell-cycle reentry.   
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9. Outlook 
 
Caveolar dysfunction: natural cause of obesity-driven disorders? 
 
The in-vitro data presented in this thesis and the in-vivo data discussed 
earlier, offer strong evidence for the ability of caveolar dysfunction to induce 
secondary disorders of obesity such as T2DM and cardiovascular disorders.  
The reduction in the levels of two essential components of caveolae in 
obesity raises the possibility of caveolar dysfunction to occur in obese 
patients. However, it remains to be investigated if caveolar dysfunction can 
indeed be a natural cause of obesity-induced secondary disorders. This can 
be experimentally verified in in ob/ob mice and obese patients by checking 
the structural and functional integrity of caveolae using microscopic analysis 
and functional studies respectively.  Conversely, one could also look at the 
susceptibility of transgenic mice overexpressing caveolin-1/3 to high-fat diet 
induced obesity, insulin resistance and cardiovascular disorders.  
Additionally this mouse can be crossed with ob/ob mice and the same 
experiments can be performed. 
 
Role of PAI-1 in mediating caveolar dysfunction induced disorders 
 
We have shown that caveolin-1 knock-down leads to PAI-1 upregulation in-
vitro. To verify this in-vivo, plasma PAI-1 levels in caveolin-1 knock out mice 
needs to be measured. If the PAI-1 levels are elevated as expected, then it 
would be of considerable interest to study the role of PAI-1 in mediating the 
secondary disorders. This can be achieved by studying the effect of PAI-1 
inhibitors in retarding the insulin resistance and vascular disorders observed 
Cav-1 KO mice. Another approach would be to cross Cav-1 KO mice with 
PAI-1 KO mice and study the insulin sensitivity and vascular function in the 
offspring. It would also be interesting to test how effective inhibitors of E2F-
pRB inhibitors are in inhibiting PAI-1 production. 
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11. Appendix-1: Chief components of the 
plasminogen System 
Plasminogen consists of 791 amino acids as determined by cDNA 
sequencing, although originally 790 amino acids were identified by protein 
sequencing. It is organized in seven structural domains, comprising a 
"preactivation peptide" (amino acid residues 1-77), 5 sequential homologous 
kringle domains (disulfide bonded triple loop structures of about 80 residues 
each), and the proteinase domain (residues 562-791). The kringle domains 
contain lysine-binding sites that play a crucial role in the specific binding to 
fibrin, cell surfaces and 2-antiplasmin. Plasminogen is converted to plasmin 
by cleavage of a single Arg561-Val562 peptide bond.  
Tissue-type plasminogen activator (t-PA) consists of 530 amino acids, 
although originally 527 were identified. It is composed of several domains 
with homologies to other proteins: a finger domain (residues 4-50), a growth 
factor domain (residues 50-87), two kringles of about 80 residues, and the 
protease domain (residues 276-527), comprising the catalytic triad. Binding 
of t-PA to fibrin is most likely mediated via the finger and the second kringle 
domains.  
Urokinase-type plasminogen activator (u-PA) is composed of an 
epidermal growth factor domain, one kringle domain and a protease domain 
containing the catalytic triad. The epidermal growth factor domain is 
responsible for the binding of u-PA to its receptor, which is present on the 
surface of a variety of cells. Single chain u-PA is converted to two chain u-
PA by cleavage of the Lys158-Ile159 peptide bond.  
2-Antiplasmin ( 2-AP, 2-plasmin inhibitor) was originally isolated as a 
glycoprotein containing 452 amino acids but it was later shown that native 
2-AP contains 464 amino acids. It is unique among serpins by having a 
COOH-terminal extension of 51 amino acid residues, which contains a 
binding site that reacts with the lysine-binding sites of both plasminogen and 
plasmin. The NH2-terminal Gln14 residue of 2-AP (Gln2 in the original 
numbering system) can cross-link to A -chains of fibrin, in a process which 
requires Ca2+ and is catalyzed by activated coagulation factor XIII.  
The two most important plasminogen activator inhibitors (PAIs) are PAI-1 
and PAI-2. PAI-1 is stabilized by a tight binding to the cell adhesion protein 
vitronectin. PAI-2 exists in two different forms with comparable kinetic 
properties, a 47 kDa intracellular non-glycosylated form with pI 5.0 and a 60 
kDa secreted glycosylated form.  
The specific cell surface u-PA receptor (u-PAR) is synthesized as a 313 
amino acid polypeptide, which is post-translationally processed at the 
COOH-terminus into a protein of 283 amino acids anchored to the plasma 
membrane by a glycosyl phosphatidylinositol (GPI) moiety. It binds all forms 
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of u-PA containing an intact growth factor domain, with high affinity. It is 
composed of three distantly related homologous structural domains, of which 
the NH2-terminal one binds u-PA.  
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